Accepted Manuscript

Enantioselective synthesis of BE ring analogues of methyllycaconitine

Emma Dickson, Lisa I. Pilkington, Margaret A. Brimble, David Barker

PII: S0040-4020(15)30241-6
DOI: 10.1016/j.tet.2015.11.057

Reference: TET 27314

To appear in: Tetrahedron

Received Date: 27 August 2015

Revised Date: 10 November 2015 Accepted Date: 24 November 2015

Please cite this article as: Dickson E, Pilkington LI, Brimble MA, Barker D, Enantioselective synthesis of BE ring analogues of methyllycaconitine, *Tetrahedron* (2015), doi: 10.1016/j.tet.2015.11.057.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Enantioselective synthesis of BE ring analogues of methyllycaconitine

Emma Dickson, Lisa I. Pilkington, Margaret A. Brimble* and David Barker*

School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland, New Zealand

methyllycaconitine

BE ring analogues

Enantioselective synthesis of BE ring analogues of methyllycaconitine

Emma Dickson, Lisa I. Pilkington, Margaret A. Brimble* and David Barker*

School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland, New Zealand

Corresponding authors. Tel.: +64-9-373-7599; fax: +64-64-373-7422;

E-mail: d.barker@auckland.ac.nz; m.brimble@auckland.ac.nz

Abstract: The enantioselective synthesis of decahydroquinolines mimicking the BE rings of methyllycacontine (MLA) is reported. The analogues were synthesised via a one-pot cyclisation using ethyl α -(bromomethyl)acrylate, (R)-1-phenylethanamine and cyclohexanone to form chiral octahydroquinolines which can be selectively hydrogenated to form the 3-substituted-decahydroquinolines with the same stereochemistry found in MLA. The amine and ketone components in the one-pot reaction can also be altered to provide access to structurally related heterocycles.

Key words: Multi-component reaction; quinolones; methyllycaconitine; enantioselective synthesis

1. Introduction

Methyllycaconitine (MLA) **1**, first discovered by Manske in 1938, is the 2-[2-(S)-methylsuccinimido]benzoate ester of the norditerpenoid alkaloid lycoctonine **2** and is the major toxic component in *Delphinium brownii*. An essential structural feature of MLA **1**, this *N*-substituted anthranilate ester is postulated to be a key pharmacophore in the molecule. It has been proposed that at physiological pH the tertiary amine in the E ring system of MLA **1** is protonated and together with the ester form a homocholine motif which mimics acetylcholine. It is also predicted that the methylsuccinimido moiety may help to maintain the correct geometry between the tertiary nitrogen atom of the piperidine E ring in the alkaloid with the carbonyl oxygen of the ester bond.




Figure 1. Methyllycaconitine 1 and lycoctonine 2

The primary mode of action of methyllycaconitine 1 is through competitive blockade at the nicotinic acetylcholine receptors (nAChRs) and whilst methyllycaconitine binds to all subtypes of nAChRs it has high affinity to the α 7 nAChR subtype. The α 7 nAChR subtype is amongst the most common in the brain and has been linked to pain, neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease as well as psychiatric disorders such as schizophrenia and depression. MLA 1 is one of only a handful of compounds, which also include the poison frog alkaloid $235B^6$ and the peptide toxins α -bungarotoxin and α -conotoxin ImI, that bind with high affinity and selectivity to the α 7 nAChR. Additionally, methyllycaconitine 1 is reported to be one of the most potent, non-protein, competitive α 7 nAChR antagonists presently available.

Structure–activity relationship studies on MLA **1** have shown that the *N*-substituted anthranilate ester moiety is essential for potent pharmacological activity.² This can be seen through comparison of the neuronal activity of MLA **1** and lycoctonine **2**; it has been established that lycoctonine **2**, which does not contain this structural feature, exhibits 2000 times less affinity for rat neuronal α7 nAChRs than MLA **1** (Figure 1).² Similarly, removal of the *N*-ethyl group in the E ring results in a greater than 10-fold reduction in potency.⁸ Of additional

1

note, a structure–activity relationship study of simple E ring analogues by Bergmeier *et al.*⁹ demonstrated that the *N*-3-phenylpropyl moiety in comparison to the natural *N*-Et group resulted in a significant increase in binding affinity.

In the hexacyclic core structure of methyllycaconitine **1** the key piperidine E ring is embedded within an azabicyclo[3.3.1]nonane and a decahydroquinoline, forming the AE and BE ring systems respectively. Many groups, ^{9,10,11} including our own, ¹⁰ have synthesised analogues of these alkaloids and most previous syntheses have focused on constructing azabicyclo[3.3.1]nonanes^{10,11} to mimic the AE rings, whilst others have worked specifically on the synthesis of piperidine E-ring analogues **2** (Figure 1). There are, however, only two reported examples of BE ring analogues, both of which were racemic analogues and only in one was the pharmacologically important anthranilate ester moiety introduced.¹²

We have previously reported¹² the synthesis of racemic BE ring analogues using a one-pot bicyclization reaction of cyclohexanone and non-volatile amines to form the core octahydroquinoline. We now herein report the enantioselective synthesis of the decahydroquinoline BE rings of methyllycaconitine as well as a number of bicyclic analogues of the BE ring system.

2. Results and Discussion

Our synthetic strategy to the bicyclic compounds utilizes a one-pot reaction involving, a primary amine, ethyl α-(bromomethyl)acrylate 3 and a cyclic ketone and is based on a method first reported by Hori et al. for the synthesis of ergot alkaloids. ¹³ We previously demonstrated the method could be applied using cyclohexanone **4a** and non-volatile amines to afford octahydroquinolines in good yields. All previous examples of this condensation utilized a cyclohexanone^{12,13} as the ketone component, therefore we first wished to determine whether other cyclic ketones could be used to provide alternative heterocyclic systems. 3,5-cis-Dimethylcyclohexanone **4b** was prepared from the hydrogenation of 3,5-dimethyl-2-cyclohexen-1-one, ¹⁴ whilst commercially available cyclohexanone 4a, cycloheptanone 4c and cyclopentanone 4d were also chosen. Ethyl α -(bromomethyl)acrylate 3 was prepared from ethyl acrylate using literature methods. ¹⁵ Ketones 4a-d were then reacted with acrylate 3 and benzylamine 5a and gave bicycles 6a-c in similar 70-76% yields (Table 1, entries 1-3). The 5/6-fused bicycle 6d formed from cyclopentanone 4d and benzylamine 5a was obtained in only 13% yield (Table 1, entry 4). To expand our study we then tested the reaction with alternative primary amines, 3phenylpropylamine 5b and chiral amine (R)- α -methyl benzylamine 5c, again using ketones 4a-d (Table 1, entries 5-12). The yields of the bicyclic compounds 6e-j were similar to those produced using benzylamine 5a, with reactions involving cyclopentanone 4d again giving bicycles 6k,l in lower yields. Bicycles 6f,h,j,l were obtained as single diastereomers, which were later determined to have an S configuration at C-3 (see below). The lower yields of the 5/6-fused bicyles 6d,k,l are presumably due to the unfavourable formation of this more strained ring system. Due to the fact that these compounds 6d,k,l were obtained in low yields and were found to be unstable even when stored at low temperatures, only the elaboration of bicycles 6a-c,e-j was pursued. Bicycles 6b,g,h were obtained as single diastereomers with NOESY correlations between H-5 and H-7 indicating the methyl groups at these positions were syn. However, the relative stereochemistry between H-3 and H-5/7 could not be determined.

With bicycles **6a-c,e-j** mimicking the BE rings of methyllycaonitine in hand, we turned to the hydrogenation of the tetrasubstituted alkene to obtain the *cis* stereochemistry which is found in ring systems of MLA **1**. Bicycles **6a-c,e-j** were hydrogenated (1 atm.) over Adam's catalyst (PtO₂)¹³ in ethyl acetate for 18 h to afford the corresponding saturated bicycles **7a-i** (Scheme 1). Purification of the bicycles was performed using basic alumina, as significant loss of product was found when silica gel was used. Hydrogenation of the unsubstituted octahydroquinolines **6a,e,f** gave decahydroquinolines **7a-c** in 41–72% yield, while hydrogenation of the 6/7-fused bicycles **6c,i,j** and dimethyl-substituted octahydroquinolines **6b,g,h** gave saturated bicycles **7d-h** in generally lower yields, whilst **7i** was not formed and only a complex mixture obtained. In all cases only the *cis-syn* stereochemistry was obtained, as confirmed by the observation of NOESY correlations between 4a-H and both 8a-H (9a-H in the case of **7d-f**) and 3-H, thus establishing the relative stereochemistry to be the same as that found in MLA **1** (Figure 2). The stereochemistry was further confirmed when a subsequent derivative was found to be suitable for X-ray crystallographic analysis (see below). Decahydroquinolines **7g** and **7h** were isolated as single diastereomers where the relationship between H-5/7 and H-3/4a/8a could not be determined thus **7g** and **7h** are either the 3*S**,4a*S**,5*R**,7*S**,8a*R** or 3*S**,4a*S**,5*S**,7*R**,8a*R** diastereomers.

Table 1: Synthesis of bicyclic aminoesters 6 and 7 MANUSCRIPT

Br
$$CO_2Et$$
 CO_2Et CO_2ET

Entry	Ketone	Amine	Bicycle 6 (Yield %)	Bicycle 7 (Yield %)
1	1	Ph NH ₂	CO ₂ Et	H CO ₂ Et
_	4a	5a	N 6a (70%) CH₂Ph	7a (54%)
2	cis-4b	5a	CO ₂ Et N 6b (76%)* CH ₂ Ph	CH ₂ Ph 5 H 4 3 CO ₂ Et 6 8a 4a 3 7 8 H 1 7 g (42%)* CH ₂ Ph
3	4 c	5a	CO ₂ Et N 6c (75%) CH ₂ Ph	CO ₂ Et 7d (58%) CH ₂ Ph
4	4d	5a	CO ₂ Et N 6d (13%) CH ₂ Ph	NA
5	4 a	Ph NH ₂	CO ₂ Et N 6e (60%) (CH ₂) ₃ Ph	Tb (41%) (CH ₂) ₃ Ph
6	4 a	Ph NH ₂ 5c	CO ₂ Et 6f (84%)	CO ₂ Et 7c (72%)
7	4 b	5b	7 8 8a N1 2 6g (43%)* (CH ₂) ₃ Ph	H CO ₂ Et 7h (43%)* (CH ₂) ₃ Ph
8	4b	5c	CO ₂ Et 6h (30%)*	7i Complex mixture
9	4c	5b	CO ₂ Et 6i (62%) (CH ₂) ₃ Ph	H CO ₂ Et 7e (54%) (CH ₂) ₃ Ph
10	4c	5c	6j (64%)	H CO ₂ Et 7f (52%)
11	4d	5b	CO ₂ Et 6k (17%) (CH ₂) ₃ Ph	NA
12	4d	5c	N 6I (14%)	NA

NA = not attempted. * The relationship between the syn 5/7-dimethyl groups and H-3 could not be determined.

Figure 2. Relative stereochemistry of saturated bicycles **7** determined by nOe interactions between H-3, H-4a and H-8a.

With the saturated bicycles mimicking the BE rings of MLA now formed, the addition of the 2-(2-methylsuccinimido)benzoate ester was required (Scheme 1, Table 2). This was achieved by reduction of the ethyl esters **7a-h** using LiAlH₄ in THF to afford alcohols **8a-h** in quantitative yield. After purification, alcohol **8c** bearing the chiral (*R*)-α-methyl benzylamine moiety was obtained as a crystalline solid suitable for X-ray crystallographic analysis (Figure 3). The X-ray crystal structure confirmed the stereochemistry between H-4a, H-8a and H-3 and established the absolute stereochemistry of the bicycle to be 3*S*,4a*R*,8a*R*, which is the same as that found in MLA **1**. The final steps were to install the succinimido anthranilate ester pharmacophore of MLA **1**. This was achieved firstly by the DCC (2 equiv.), DMAP (0.1 equiv.) mediated coupling of 2-(3-methyl-2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)benzoic acid **9**¹⁶ (2.0 equiv.) with alcohols **8a-h**, in CH₂Cl₂, and afforded anthranilate esters **10a-h** in 53–95% yields. Finally the maleimide unit in anthranilates **10a-h** was hydrogenated over 10% palladium on charcoal (1 atm.) for 18 h to yield the desired succinimido anthranilates **11a-h** in near quantitative yields. This reaction gave succinimido anthranilates **11a-h** as 1:1 mixtures of diastereomers at the C-3" position. Preparation of enantiopure succinimido anthranilates has previously been achieved via the three step process^{10q,16} however biological assessment has shown diastereomeric mixtures have similar activity to single isomers. ^{9h,101}

Scheme 1. Synthesis of succinimido anthranilates 11.

ACCEPTED MANUSCRIPT

 Table 2: Synthesis of succinimido anthranilates 11.

Bicycles 7/8 (R = CO ₂ Et, 7 ; R = CH ₂ OH, 8)	Anthranilate ester 10	Succinimido anthranilate 11	Yield from 7 (three steps)
H R R 7a/8a CH ₂ Ph	H N O N O CH ₂ Ph 10a	H O N O N O N O N O 11a	51%
H R 7b/8b (CH ₂) ₃ Ph	O N O N O (CH ₂) ₃ Ph 10b	O N O N O (CH ₂) ₃ Ph 11b	90%
R 7c/8c	H Ph 10c	H O N O	67%
R 7d/8d CH ₂ Ph	H N O N O CH ₂ Ph 10d	O NO NO CH ₂ Ph 11d	76%
H A 7e/8e H (CH ₂) ₃ Ph	H N (CH ₂) ₃ Ph 10e	O N O N O (CH ₂) ₃ Ph 11e	63%
H R 7f/8f	O NO NO Ph 10f	Ph 11f	87%
H N 7g/8g CH ₂ Ph	H N O N O CH ₂ Ph 10g	H N CH ₂ Ph 11g	68%
R H N R $Th/8h$ $(CH2)3Ph$	O N O N O (CH ₂) ₃ Ph 10h	O N O N O (CH ₂) ₃ Ph 11h	76%

Figure 3. X-ray crystal structure of 8c (available from the CCDC: 1419766).

Scheme 2. Synthesis of succinimide anthranilate 16.

The decahydroquinoline BE rings of MLA 1 have an *N*-ethyl group and we envisaged that this could be introduced by hydrogenolysis of the (*R*)-α-methyl benzylamine moiety in 7c and subsequent addition of an ethyl moiety. Whilst the α-methyl benzylamine group had not been removed upon hydrogenation over PtO₂ we found that hydrogenation of 7c over 10% palladium on charcoal (1 atm.) in MeOH for 18 h gave amine 12 in 91% yield (Scheme 2). Amine 12 was reacted immediately with acetic anhydride and DMAP in CH₂Cl₂/Et₃N (1:1) to allow acetamide 13 in quantitative yield. Acetamide 13 underwent complete degradation when subjected to chromatography with either silica or alumina and was therefore reduced immediately, using LiAlH₄, to give amino alcohol 14 in quantitative yield. Coupling of alcohol 14 with acid 9 followed by hydrogenation of the resultant maleimide 15 gave succinimido anthranilate 16 in 79% yield over two steps. Anthranilate 16 contains the complete carbon framework of the BE rings of MLA 1 including the natural *N*-ethyl substituent, with the same absolute stereochemistry as the natural product.

3. Conclusions

In conclusion we have reported the use of a three component, one-pot, cyclisation reaction to form 2,3-fused 5/6, 6/6 and 7/6 piperidine heterocycles. Subsequent transformation of the bicycles into analogues of the BE rings of MLA 1 has also been achieved. Use of a chiral (*R*)-α-methyl benzylamine auxiliary allowed the synthesis of enantiopure decahydroquinoline 7c which was converted into succinimido anthranilate 16 in 72% yield in 5 steps. This synthesis of anthranilate 16 constitutes the first asymmetric synthesis of the complete carbon framework of the BE rings of methyllycaconitine 1.

4. Experimental Section

4.1 General Experimental

Analytical thin layer chromatography (TLC) was performed using 0.2 mm thick precoated silica gel plates (Merck Kieselgel 60 F254). Compounds were visualized by ultraviolet fluorescence or by staining iodine. Flash chromatography was performed using Riedel-de Haën silica gel (0.032-0.063 mm) with the indicated solvents.

¹H NMR spectra were recorded with a Bruker DRX 300 (300 MHz) or a Bruker DRX 400 (400 MHz)

spectrometer at ambient temperature using CDCl₃ as a solvent. Chemical shifts are given in parts per million (ppm) downfield shift from tetramethylsilane as an internal standard, and reported as position (δ), multiplicity (s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of doublets, ddt = doublet of doublet of triplets, dt = doublet of triplets, m = multiplet, t = triplet, td = triplet of doublets, q = quartet), relative integral, assignment and coupling constant (J in Hz). ¹³C NMR spectra were recorded with a Bruker DRX 300 (75 MHz) or a Bruker DRX 400 (100 MHz) spectrometer at ambient temperature with complete proton decoupling. Chemical shifts are expressed in parts per million referenced to the residual chloroform peak (δ = 77.0 ppm), and reported as position (δ) and assignment, aided by DEPT 135 experiments. In addition, ¹H-¹H-COSY, ¹H-¹H-NOESY and ¹H-¹³C-HSQC correlation spectra were used for the complete assignment of the proton and carbon resonances. High resolution mass spectra were recorded with a VG-70SE mass spectrometer. Ionisation method employed was electron impact (EI) or electrospray ionization (ESI). Melting points were determined on a Kofler hot-stage apparatus and are uncorrected. [α]_D²⁰ values are given in 10⁻¹ deg cm³ g⁻¹. Ethyl 2-(bromomethyl)acrylate 3¹⁵ and 2-(3-methyl-2,5-dioxo-2,5-dihydropyrrol-1-yl)benzoic acid 9¹⁶ were prepared as reported. X-ray crystal structures were obtained using a Bruker SMART platform goniometer with a CCD area detector at 150 K with structural solution and refinement by SHELXTL software package.

4.1.1 3,5-cis-Dimethylcyclohexanone **4b**. To a solution of 3,5-dimethyl-2-cyclohexeneone (0.400 g, 3.22 mmol) in isopropanol (4.0 mL) was added 10% palladium on carbon (0.04g, 0.38 mmol) and the resulting mixture was stirred under an atmosphere of hydrogen for 2 h. The mixture was filtered through Celite and washed with further isopropanol (20 mL) and the solvent was removed *in vacuo* to give the *title compound* **4b** (0.406 g, 100%) as a pale blue/green oil that was used immediately without further purification; 1 H NMR (400 MHz; CDCl₃): δ = 1.02 (6H, d, J = 5.8 Hz, 3-CH₃ and 5-CH₃), 1.78-1.97 (4H, m, H-3, H-4, H-5), 2.33 (4H, d, J = 11.8 Hz, H-2 and H-6). 13 C NMR (100 MHz, CDCl₃) 22.3 (3-CH₃ and 5-CH₃), 33.2 (C-3 and C-5), 42.8 (C-4), 49.2 (2 x CH₂, C-2 and C-6), 212.11 (q, COO). The spectroscopic data was consistent with literature values. 14

4.2 General Method A: Three component synthesis of bicycles 6. To amine **5** (6.0 mmol) in toluene (32 mL) was added dropwise ethyl 2-(bromomethyl)acrylate **3** (3.00 mmol) in toluene (5 mL) at 0 °C. After 15 min a solution of cyclic ketone **4** (3.00 mmol) in toluene (5 mL) was added and the reaction mixture was heated under reflux under N_2 for 18 h using a Dean-Stark trap containing 5 Å molecular sieves. The mixture was cooled and extracted with 1 M HCl (2 × 100 mL). The combined aqueous layers were washed with ethyl acetate (100 mL), basified with solid Na_2CO_3 and then extracted with CH_2Cl_2 (3 × 75 mL). The extract was dried Na_2SO_4 and concentrated *in vacuo*. The crude product was purified by column chromatography using silica gel to give the desired unsaturated bicycle **6**.

4.2.1 Ethyl 1-benzyl-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate **6a**. Using general method A, benzyl amine **5a** (0.655 mL, 6.0 mmol) and cyclohexanone **4a** (0.310 mL, 3.0 mmol) after purification by flash chromatography (20% ethyl acetate in *n*-hexanes) gave the *title compound* **6a** (0.632 g, 70%) as a bright yellow oil; $R_F = 0.68$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3025, 2927, 2836, 1727, 1176, 1027; ¹H NMR (300 MHz; CDCl₃): δ = 1.21 (3H, t, J = 7.0 Hz, OCH₂CH₃), 1.55-1.73 (4H, m, H-6 and H-7), 1.81-2.14 (3H, m, H-5 and H_A-8), 2.15-2.26 (3H, m, H-4 and H_B-8), 2.61-2.75 (1H, m, H-3), 2.91 (1H, t, J = 11.3 Hz, H_A-2), 3.14 (1H, ddd, J = 1.9, 3.3, 11.3 Hz, H_B-2), 3.96-4.06 (2H, m, NCH₂Ph), 4.07-4.13 (2H, m, OCH₂CH₃), 7.22-7.33 (5H, m, Ar-H); ¹³C NMR (75.5 MHz; CDCl₃): δ = 14.14 (OCH₂CH₃), 23.0 (C-7), 23.6 (C-6), 26.7 (C-5), 29.9 (C-8), 31.2 (C-4), 37.6 (C-3), 50.0 (C-2), 53.8 (NCH₂Ph), 60.2 (OCH₂CH₃), 106.3 (C-4a), 126.7 (Ar-CH), 127.6 (Ar-CH), 128.19 (Ar-CH), 135.9 (q, C-8a), 140.12 (Ar-C) and 174.5 (q, COO); MS (EI): m/z = 299 (M⁺, 76%), 226 (25), 208 (75), 91 (100); HRMS (EI): $C_{19}H_{25}NO_2$ requires 299.18853; found: 299.18823.

4.2.2 Ethyl 1-benzyl-5,7-dimethyl-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate **6b**. Using general method A, benzylamine **5a** (0.568 mL, 5.2 mmol) and 3,5-cis-dimethylcyclohexanone **4b** (0.372 mL, 2.6 mmol) after purification by flash chromatography (20% ethyl acetate in *n*-hexanes) gave the *title compound* **6b** (0.605 g, 76%) as a pale yellow oil. $R_F = 0.75$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3019, 2951, 2907, 1729, 1453, 1171, 1028; ¹H NMR (400 MHz; CDCl₃): $\delta = 0.80$ -0.92 (1H, m, H_A-6), 0.96 (3H, d, J = 6.2 Hz, 5-CHC H_3), 1.00 (3H, d J = 6.6 Hz, 7-CHC H_3), 1.22 (3H, t, J = 7.0 Hz, OCH₂CH₃), 1.61-1.79 (3H, m, H-4 and H_B-6), 1.99 (1H, dd, J = 3.0, 15.8 Hz, H_A-8), 2.12-2.25 (2H, m, H-5 and H-7), 2.35 (1H, td, J = 3.0, 13.6 Hz, H_B-8), 2.67 (1H, tdd, J = 2.8, 5.2 and 11.3 Hz, H-3), 2.78 (1H, t, J = 11.3 Hz, H_A-2), 3.13 (1H, dt, J = 2.8, 11.3 Hz, H_B-2), 3.95-4.02 (1H, m, NCH_AH_BPh), 4.05-4.13 (2H, m, CO₂CH₂CH₃), 4.14-4.27 (1H, m, NCH_AH_BPh) and 7.20-7.36 (5H,

m, Ar-H); 13 C NMR (100 MHz, CDCl₃); δ = 14.2 (OCH₂CH₃), 20.5 (7-CHCH₃), 22.2 (5-CHCH₃), 29.2 (C-8), 35.2 (C-5 and C-7), 35.7 (C-4), 38.3 (C-3), 41.6 (C-6), 49.9 (C-2), 53.9 (NCH₂Ph), 60.3 (OCH₂CH₃), 109.1 (C-4a), 126.7 (Ar-CH), 127.5 (Ar-CH), 128.3 (Ar-CH), 135.9 (C-8a), 140.1 (Ar-C) and 174.8 (COO); HRMS (ESI): m/z [MH]⁺ C₂₁H₃₀NO₂ requires 328.2270; found 328.2271.

4.2.3 Ethyl 1-benzyl-2,3,4,5,6,7,8,9-octahydro-1H-cyclohepta[b]pyridine-3-carboxylate **6c**. Using general method A benzylamine **5a** (0.568 mL, 5.2 mmol) and cycloheptanone **4c** (0.306 mL, 2.6 mmol) after purification by flash chromatography (33% ethyl acetate in *n*-hexanes) gave the *title compound* **6c** (0.611g, 75%) as a bright yellow oil. $R_F = 0.7$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3063, 3035, 2915, 2843, 1728, 1454, 1155; ¹H NMR (400 MHz; CDCl₃) $\delta = 1.21$ (3H, t, J = 7.2 Hz, OCH₂CH₃), 1.30-1.51, 1.54-1.75, 1.76-1.87 and 2.19-2.43 (10H, 4 x m, H-5, H-6, H-7, H-8 and H-9), 2.02-2.16 (2H, m, H-4), 2.54-2.64 (1H, m, H-3), 2.68-2.79 (1H, m, H_A-2), 3.03-3.12 (1H, m, H_B-2), 3.55-3.64 (1H, m, NCH_ACH_BPh), 4.03-4.14 (3H, m, NCH_ACH_BPh and OCH₂CH₃) and 7.16-7.39 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 14.2$ (OCH₂CH₃), 27.0, 27.6, 32.2, 32.3 and 32.5 (C-5, C-6, C-7, C-8 and C-9), 33.6 (C-4), 35.6 (C-3), 49.4 (C-2), 54.4 (NCH₂Ph), 60.2 (OCH₂CH₃), 116.0 (C-4a), 126.9 (Ar-CH), 127.9 (Ar-CH), 128.1 (Ar-CH), 139.9 (q, C-9a), 143.3 (Ar-C), 174.7 (COO); HRMS (ESI): m/z: [MH]⁺ C₂₀H₂₈NO₂ requires 314.2115; found 314.2115.

4.2.4 Ethyl 1-benzyl-2,3,4,5,6,7-hexahydro-1H-cyclopenta[b]pyridine-3-carboxylate **6d**. Using general method A benzylamine **5a** (0.568 mL, 5.2 mmol) and cyclopentanone **4d** (0.230 mL, 2.6 mmol) after purification by flash chromatography (66% ethyl acetate in *n*-hexanes) gave the *title compound* **6d** (0.101 g, 13%) as a brown oil. $R_F = 0.65$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3469, 2934, 2843, 1727, 1452, 1367, 1179; ¹H NMR (400 MHz; CDCl₃) $\delta = 1.21$ (3H, t, J = 7.5 Hz, OCH₂CH₃), 1.83-1.94 (2H, m, H-6), 2.17-2.34 (3H, m, H-4, H_A-5), 2.37-2.44 (1H, m, H_B-5), 2.45-2.53 (2H, m, H-7), 2.70-2.80 (1H, m, H-3), 2.93 (1H, t, J = 11.5 Hz, H_A-2), 3.08-3.15 (1H, m, H_B-2), 4.02-4.17 (4H, m, NCH₂Ph and OCH₂CH₃), 7.20-7.39 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 14.1$ (OCH₂CH₃), 20.8 (C-6), 26.9 (C-4), 31.2 (C-7), 34.0 (C-5), 39.0 (C-3), 49.5 (C-2), 55.6 (NCH₂Ph), 60.3 (OCH₂CH₃), 106.6 (C-4a), 126.8 (Ar-CH). 127.7 (Ar-CH), 128.3 (Ar-CH), 139.3 (Ar-C), 141.8 (C-7a), 174.4 (COO); HRMS (ESI): $m/z = [MH^+]$ C₁₈H₂₄NO₂ requires 286.1802; found 286.1810.

4.2.5 Ethyl 1-(3-phenylpropyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate **6e**. Using general method A 3-phenylpropylamine **5b** (0.854 mL, 6.0 mmol) and cyclohexanone **4a** (0.310 mL, 3.0 mmol) after purification by flash chromatography (20% ethyl acetate in *n*-hexanes) gave the *title compound* **6e** (0.589 g, 60%) as a pale yellow oil. $R_F = 0.8$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3025, 2925, 2857, 1727, 1496, 1379, 1260, 1176, 1026; ¹H NMR (300 MHz; CDCl₃) δ = 1.25 (3H, t, J = 6.8 Hz, OCH₂CH₃), 1.43-1.79 (4H, m, H-6 and H-7), 1.72-1.79 (2H, m, NCH₂CH₂CH₂Ph), 1.82-1.90 (4H, m, H-5 and H-8), 1.97-2.03 (2H, m, H-4), 2.59 (2H, dt, J = 2.7, 8.3 Hz, NCH₂CH₂CH₂Ph), 2.71 (1H, ddt, J = 3.3, 5.7, 11.8 Hz, H-3), 2.86-2.99 (3H, m, H_A-2 and NCH₂CH₂CH₂Ph), 3.20 (1H, ddd, J = 1.8, 3.3, 11.8 Hz, H_B-2), 4.15 (2H, m, OCH₂CH₃), 7.17-7.28 (5H, m, Ar-H); ¹³C NMR (75.5 MHz; CDCl₃) δ = 14.2 (OCH₂CH₃), 22.9 (C-7), 23.6 (C-6), 26.4 (NCH₂CH₂CH₂Ph), 29.7 (C-8), 29.9 (C-5), 31.2 (C-4), 33.36 (NCH₂CH₂CH₂Ph), 38.1 (C-3), 50.0 (NCH₂CH₂CH₂Ph), 50.2 (C-2), 60.3 (OCH₂CH₃), 106.1 (C-4a), 125.7 (Ar-CH), 128.3 (2 x Ar-CH), 135.8 (q, C-8a), 142.0 (Ar-C), 174.6 (COO); MS (EI): m/z = 327 (M⁺, 4%), 222 (10), 91 (55); HRMS (EI): C₂₁H₂₉NO₂ requires 327.2198; found 327.2197.

4.2.6 (3S)-Ethyl 1-((R)-1-phenylethyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate **6f**. Using general method A, (R)-1-phenylethylamine **5c** (0.727 mL, 6.0 mmol) and cyclohexanone **4a** (0.310 mL, 3.0 mmol) after purification by flash chromatography (20% ethyl acetate in *n*-hexanes) gave the *title compound* **6f** (0.789 g, 84%) as a bright yellow oil. $[\alpha]_D^{20} + 39$ (c 0.89, CHCl₃); $R_F = 0.70$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3021, 2930, 2846, 1727, 1446, 1371, 1176, 1026; ¹H NMR (300 MHz; CDCl₃) δ = 1.94 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.43 (3H, d, J = 7.0 Hz, NCH(CH₃)Ph), 1.60-1.77 (4H, m, H-6 and H-7), 1.85-2.08 (3H, m, H-5 and H_A-8), 2.13-2.36 (3H, m, H-4 and H_B-8), 2.61-2.70 (2H, m, H_A-2 and H-3), 2.98-3.10 (1H, m, H_B-2), 3.99-4.17 (2H, m, OCH₂CH₃), 4.73-4.81 (1H, m, NCH(CH₃)Ph), 7.23-7.40 (5H, m, Ar-H); ¹³C NMR (75 MHz; CDCl₃) δ = 14.1 (OCH₂CH₃), 15.5 (NCH(CH₃)Ph), 23.1 (C-7), 23.9 (C-6), 26.7 (C-5), 30.1 (C-8), 30.3 (C-4), 38.1 (C-3), 44.9 (C-2), 53.3 (NCH(CH₃)Ph), 60.1 (OCH₂CH₃), 105.6 (C-4a), 126.5 (Ar-CH), 127.2 (Ar-CH), 128.6 (Ar-CH), 134.5 (C-8a), 143.3 (Ar-C), 174.7 (COO); HRMS (ESI): $m/z = [M]^+ C_{20}H_{27}NO_2$ requires 313.20418; found 313.20420.

4.2.7 Ethyl 5,7-dimethyl-1-(3-phenylpropyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate **6g**. Using general method A 3-phenylpropylamine **5b** (0.740 mL, 5.2 mmol) and 3,5-cis-dimethylcylohexanone **4b** (0.372 mL, 2.6 mmol) after purification by flash chromatography (33% ethyl acetate in *n*-hexanes) gave the *title compound* **6g** (0.400 g, 43%) as a pale yellow oil. $R_F = 0.6$ (3:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3028, 2956, 2925, 1721, 1451, 1188, 1028; ¹H NMR (400 MHz; CDCl₃) $\delta = 0.75$ -0.84 (1H, m, H_A-6), 0.92 (3H, d, J = 6.2 Hz, 5-CHC- H_3), 0.95 (3H, d, J = 6.8 Hz, 7-CHC H_3), 1.26 (3H, t, J = 7.2 Hz, OCH₂CH₃), 1.44-1.54 (1H, m, H_A-4), 1.50-1.61 (1H, m, H-5), 1.62-1.70 (1H, m, H_B-6), 1.66-1.70 (1H, m, H_A-8), 1.78-1.87 (1H, m, H_B-8), 1.89-1.97 (1H, m, NCH₂CH_AH_BCH₂Ph), 1.98-2.05 (1H, m, H_B-4), 2.06-2.14 (1H, m, H-7), 2.25-2.35 (NCH₂CH_AH_BCH₂Ph), 2.58 (2H, t, J = 7.7 Hz, NCH₂CH₂CH₂Ph), 2.60-2.70 (1H, m, H-3), 2.84 (1H, t, J = 11.0 Hz, H_A-2), 2.91 (2H, t, J = 7.4 Hz, NCH₂CH₂CH₂Ph), 3.22 (1H, dt, J = 2.6, 11.2 Hz, H_B-2), 4.07-4.19 (2H, m, OCH₂CH₃), 7.11-7.31 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 14.2$ (OCH₂CH₃), 20.4 (7-CHCH₃), 22.1 (5-CHCH₃), 29.0 and 29.1 (C-5, C-8 and NCH₂CH₂CH₂Ph), 33.2 (NCH₂CH₂CH₂Ph), 35.2 and 35.3 (C-7 and C-4), 38.6 (C-3), 41.4 (C-6), 50.0 (C-2 and NCH₂CH₂CH₂Ph), 60.2 (OCH₂CH₃), 109.2 (C-4a), 125.6 (Ar-CH), 128.8 (Ar-CH), 128.3 (Ar-CH), 135.7 (C-8a), 141.9 (Ar-C), 174.8 (COO); HRMS (ESI): $m/z = [MH]^+$ C₂₃H₃₄NO₂ requires 356.2584; found 356.2590.

4.2.8 (3S)-Ethyl 5,7-dimethyl-1-((R)-1-phenylethyl)-1,2,3,4,5,6,7,8-octahydroquinoline-3-carboxylate **6h**. Using general method A (R)-1-phenethylamine **5c** (0.670 mL, 5.2 mmol) and 3,5-cis-dimethylcylohexanone **4b** (0.372 mL, 2.6 mmol) after purification by flash chromatography (33% ethyl acetate in *n*-hexanes) gave the *title compound* **6h** (0.266 g, 30%) as a pale yellow oil. $R_F = 0.65$ (3:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2906, 2870, 1729, 1448, 1371, 1170; ¹H NMR (400 MHz; CDCl₃) $\delta = 0.82$ -0.92 (1H, m, H_A-6), 0.99 (6H, d, J = 6.7 Hz, 5-CHC H_3 and 7-CHC H_3), 1.21 (3H, t, J = 7.0 Hz, OCH₂C H_3), 1.47 (CH₃, d, J = 7.4 Hz, NCH(C H_3)Ph), 1.65-1.81 (3H, m, H-5, H_B-6 and H-7), 1.93-2.00 (1H, m, H_A-8), 2.15-2.21 (1H, m, H_A-4), 2.23-2.33 (1H, m, H_B-8), 2.36-2.50 (2H, H_A-2 and H_B-4), 2.55-2.63 (1H, m, H-3), 3.07-3.14 (1H, m, H_B-2), 4.03-4.16 (2H, m, OCH₂CH₃), 4.90 (1H, q, J = 7.4 Hz, NCH(CH₃)Ph), 7.19-7.39 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 14.2$ (OCH₂CH₃), 17.0 (NCH(CH₃)Ph), 20.7 (7-CHCH₃), 22.3 (5-CHCH₃), 29.3 (C-5 or C-7), 29.5 (C-8), 35.46 (C-5 or C-7 and C-4), 39.6 (C-3), 41.5 (C-6), 44.5 (C-2), 53.1 (NCH(CH₃)Ph), 60.2 (OCH₂CH₃), 108.3 (C-4a), 126.5 (Ar-CH), 127.5 (Ar-CH), 128.2 (Ar-CH), 134.8 (C-8a), 142.9 (Ar-C) and 175.1 (COO); HRMS (ESI) $m/z = [MH]^+$ C₂₂H₃₂NO₂ requires 342.2428; found 342.2434.

4.2.9 Ethyl 1-(3-phenylpropyl)-2,3,4,5,6,7,8,9-octahydro-1H-cyclohepta[b]pyridine-3-carboxylate **6i**. Using general method A 3-phenylpropylamine **5b** (0.740 mL, 5.2 mmol) and cycloheptanone **4c** (0.306 mL, 2.6 mmol) after purification by flash chromatography (20% ethyl acetate in *n*-hexanes) gave the *title compound* **6i** (0.551 g, 62%) as a yellow oil. $R_F = 0.5$ (2:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3025, 2919, 2848, 1726, 1453, 1158; ¹H NMR (400 MHz; CDCl₃) $\delta = 1.26$ (3H, t, J = 7.0 Hz, OCH₂CH₃), 1.19-1.34, 1.69-1.85, 1.92-2.12 and 2.15-2.30 (10H, m, H-5, H-6, H-7, H-8 and H-9), 1.47-1.65 (2H, m, NCH₂CH₂CH₂Ph), 2.48-2.85 (8H, m, H_A-2, H-3, H-4, NCH₂CH₂CH₂Ph, NCH₂CH₂Ph), 3.18-3.24 (1H, m, H_B-2), 4.09-4.17 (2H, m, OCH₂CH₃) and 7.13-7.31 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 14.2$ (OCH₂CH₃), 26.8 (NCH₂CH₂CH₂Ph), 27.0, 30.8, 31.8, 32.5 and 32.5 (C-5, C-6, C-7, C-8 and C-9), 33.3 and 36.1 (C-4 and NCH₂CH₂CH₂Ph), 36.1 (C-3), 49.6 (C-2), 50.4 (NCH₂CH₂CH₂Ph), 60.3 (OCH₂CH₃), 115.1 (C-4a), 125.7 (Ar-CH), 128.3 (2xArCH), 142.1 (C-9a), 143.5 (Ar-C), 174.9 (COO); HRMS (ESI): $m/z = [MH^+] C_{22}H_{34}NO_2$ requires 344.2584; found 344.2578.

4.2.10 (3S)-Ethyl 1-((R)-1-phenylethyl)-2,3,4,5,6,7,8,9-octahydro-1H-cyclohepta[b]pyridine-3-carboxylate **6j**. Using general method A (R)-1-phenylethylamine **5c** (0.670 mL, 5.2 mmol) and cycloheptanone **4c** (0.306 mL, 2.6 mmol) after purification by flash chromatography (33% ethyl acetate in *n*-hexanes) gave the *title compound* **6j** (0.545 g, 64%) as a bright yellow oil. $[\alpha]_D^{20} + 41$ (*c* 1.0, CHCl₃); $R_F = 0.6$ (3:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3007, 2921, 2848, 1726, 1448, 1377, 1178, 1027; ¹H NMR (400 MHz; CDCl₃) δ = 1.21 (3H, t, *J* = 6.8 Hz, OCH₂CH₃), 1.44 (3H, d, *J* = 6.8 Hz, NCH(CH₃)Ph), 1.62-1.79, 2.20-2.24, 2.25-2.33 and 2.38-2.47 (10H, m, H-5, H-6, H-7, H-8 and H-9), 2.57-2.63 (3H, m, H_A-2 and H-3), 3.03-3.07 (1H, m, H_B-2), 4.07-4.22 (2H, m, OCH₂CH₃), 4.64 (1H, q, *J* = 7.0 Hz, NCH(CH₃)Ph), 7.19-7.48 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) δ = 14.1 (OCH₂CH₃), 15.5 (NCH(CH₃)Ph), 26.7, 27.4, 30.8, 32.3 and 32.5 (C-5, C-6, C-7, C-8 and C-9), 33.9 (C-4), 39.1 (C-3), 45.5 (C-2), 54.8 (NCH(CH₃)Ph), 60.2 (OCH₂CH₃), 114.3 (C-4a), 126.5 (Ar-CH), 127.3 (Ar-CH), 128.4 (Ar-CH), 141.4 (C-9a), 143.7 (Ar-C), 175.0 (COO); HRMS (ESI) $m/z = [MH]^+$ C₂₁H₃₀NO₂ requires 328.2271; found 328.2278.

- 4.2.11 Ethyl 1-(3-phenylpropyl)-2,3,4,5,6,7-hexahydro-1H-cyclopenta[b]pyridine-3-carboxylate **6k**. Using general method A 3-phenylpropylamine **5b** (0.740 mL, 5.2 mmol) and cyclopentanone **4d** (0.230 mL, 2.6 mmol) after purification by flash chromatography (50% ethyl acetate in *n*-hexanes) gave the *title compound* **6k** (0.132 g, 17%) as a dark brown oil. $R_F = 0.8$ (1:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3018, 2938, 1727, 1496, 1454, 1397, 1189, 1029; ¹H NMR (400 MHz; CDCl₃) $\delta = 1.26$ (3H, t, J = 8.0 Hz, OCH₂CH₃), 1.68-1.94 (4H, m, 6-CH₂ and NCH₂CH₂CH₂Ph), 2.20-2.35 (3H, m, H_A-7 and NCH₂CH₂CH₂Ph), 2.36-2.46 (3H, m, H-5 and H_B-7), 2.64-2.71 (2H, m, NCH₂CH₂CH₂Ph), 2.78-2.93 (1H, m, H-3), 2.96-3.04 (1H, m, H_A-2), 3.25-3.32 (1H, m, H_B-2), 4.15-4.28 (2H, m, OCH₂CH₃) and 7.18-7.39 (5H, m, Ar-H); ¹³C NMR (100 MHz, CDCl₃) $\delta = 14.2$ (OCH₂CH₃), 20.9 (C-6), 27.0 (C-4), 29.4 (NCH₂CH₂CH₂Ph), 31.0 (C-5), 33.2 (NCH₂CH₂CH₂Ph), 34.0 (C-7), 39.4 (C-3), 49.5 (C-2), 51.3 (NCH₂CH₂CH₂Ph), 60.4 (OCH₂CH₃), 106.5 (C-4a), 125.8 (Ar-CH), 128.2 (Ar-CH), 128.3 (Ar-CH), 141.1 (C-7a and Ar-C) and 174.6 (COO); HRMS (EI) $m/z = [MH]^+$ C₂₀H₂₈NO₂ requires 314.2215; found 314.2112.
- 4.2.12 (3S)-Ethyl 1-((R)-1-phenylethyl)-2,3,4,5,6,7-hexahydro-1H-cyclopenta[b]pyridine-3-carboxylate **6I**. Using general method A (R)-1-phenylethylamine **5c** (0.670 mL, 5.2 mmol) and cyclopentanone **4a** (0.230 mL, 2.6 mmol) after purification by flash chromatography (50% ethyl acetate in *n*-hexanes) gave the *title compound* **6I** (0.11 g, 14%) as a brown oil. $[\alpha]_D^{20}$ +39 (*c* 1.0, CHCl₃); $R_F = 0.65$ (1:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2955, 1727, 1636, 1449, 1371, 1177, 1027; δ_H (400 MHz; CDCl₃) 1.18 (3H, t, J = 6.7 Hz, OCH₂CH₃), 1.44 (3H, d, J = 7.0 Hz, NCH(CH₃)Ph), 1.86-1.99 (2H, m, H-6), 2.17-2.27 (2H, m, H-4), 2.28-2.34 (2H, m, H-7), 2.63-2.71 (1H, m, H-3), 2.72-2.80 (1H, m, H_A-2), 2.77-2.86 (2H, m, H-5), 3.08-3.15 (1H, m, H_B-2), 4.04-4.17 (2H, m, OCH₂CH₃), 4.57-4.65 (1H, m, NCH(CH₃)Ph), 7.18-7.52 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 14.1 (OCH₂CH₃), 16.1 (NCH(CH₃)Ph), 20.9 (C-6), 27.0 (C-4), 31.4 (C-5), 34.3 (C-7), 39.6 (C-3), 44.5 (C-2), 56.2 (NCH(CH₃)Ph), 60.3 (OCH₂CH₃), 106.5 (C-4a), 126.7 (Ar-CH), 127.3 (Ar-CH), 128.2 (Ar-CH), 141.0 (Ar-C), 142.7 (C-7a), 174.8 (COO); HRMS (EI+) $m/z = [MH]^+$ C₁₉H₂₆NO₂ requires 300.1958; found 300.1965.
- **4.3** General Method B: Hydrogenation of octahydroquinolines 6 to decahydroquinolines 7. To a solution of octahydroquinoline 6 (1.0 mmol) in ethyl acetate (5.0 mL) was added platinum oxide (0.04 g, 0.17 mmol) and the resulting mixture was stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which was washed with ethyl acetate (20 mL) and the volatile solvents were removed *in vacuo* to give the crude product which was purified by chromatography on basic alumina to give the desired decahydroquinoline 7.
- 4.3.1 (3S*,4aR*,8aR*)-Ethyl 1-benzyldecahydroquinoline-3-carboxylate 7a. Using general method B octahydroquinline 6a (0.415 g, 1.4 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* 7a (0.227 g, 54%) as a pale yellow oil. $R_F = 0.70$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2927, 2836, 1727, 1660, 1176, 1027; δ_H (300 MHz; CDCl₃) 1.08-1.14 (1H, m, H_A-8), 1.21 (3H, t, J = 10.3 Hz, OCH₂CH₃), 1.31-1.39 (2H, m, H-6), 1.45-1.71 (5H, m, H_A-4, H-5, H-7), 1.72-1.92 (2H, m, H_B-4, H_B-8), 1.94-2.10 (1H, m, H-4a), 2.51-2.66 (2H, m, H_A-2, H-3), 2.67-2.80 (2H, m, H_B-2, H-8a), 3.57-3.62 (1H, m, NCH_ACH_BPh), 3.71-3.76 (1H, m, NCH_ACH_BPh), 4.10 (2H, q, J = 7.0 Hz, OCH₂CH₃) 7.16-7.31 (5H, m, Ar-H); δ_C (75.5 MHz; CDCl₃) 14.2 (OCH₂CH₃), 18.1 (C-7), 21.0 (C-6), 25.5 (C-8), 27.3 (C-4), 31.4 (C-5), 34.7 (C-4a), 42.3 (C-3), 47.0 (C-2), 58.4 (NCH₂Ph), 58.9 (C-8a), 60.1 (OCH₂CH₃), 126.7 (Ar-CH), 128.1 (Ar-CH), 128.4 (Ar-CH), 139.8 (Ar-C), 174.7 (COO); HRMS (EI+) $m/z = [M]^+$ C₁₉H₂₇NO₂ requires 301.20418; found 301.20339.
- 4.3.2 (3S*,4aR*,8aR*)-Ethyl 1-(3-phenylpropyl)decahydroquinoline-3-carboxylate **7b**. Using general method B octahydroquinline **6e** (0.350 g, 1.07 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* **7b** (0.149 g, 41%) as a pale yellow oil. $R_F = 0.75$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2928, 2861, 1727, 1451, 1369, 1247, 1155, 1031; $δ_H$ (300 MHz; CDCl₃) 1.10-1.97 (1H, m, H_A-8), 1.20 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.28-1.41 (2H, m, H-6), 1.43-1.50 (2H, m, H-7), 1.51-1.58 (2H, m, H-5), 1.61-1.73 (2H, m, H-4), 1.74-1.76 (1H, m, H_B-8), 1.79-1.87 (2H, m, NCH₂CH₂CH₂Ph), 1.94-2.01 (1H, m, H-4a), 2.45-2.53 (3H, m, H_A-2, NCH₂CH₂CH₂Ph), 2.65 (2H, t, J = 7.6 Hz, NCH₂CH₂CH₂Ph), 2.55-2.67 (1H, m, H-3), 2.68-2.73 (1H, m, H-8a), 2.78 (1H, dd, J = 2.7, 11.2 Hz, H_B-2), 4.11 (2H, q, J = 7.1 Hz, OCH₂CH₃) 7.14-7.29 (5H, m, Ar-H); $δ_C$ (75.5 MHz; CDCl₃) 14.0 (OCH₂CH₃), 17.3 (C-7), 20.2 (C-6), 25.3 (C-8), 26.9 (C-4), 29.3 (NCH₂CH₂CH₂Ph), 31.2 (C-5), 33.4 (NCH₂CH₂CH₂Ph), 34.5 (C-4a), 42.0 (C-3), 47.2 (C-2), 53.1 (NCH₂CH₂CH₂Ph), 58.4 (C-8a), 59.9 (OCH₂CH₃), 125.4 (Ar-CH), 128.0 (Ar-CH), 128.1 (Ar-CH), 142.1 (Ar-C), 174.2 (COO); HRMS (EI+) $m/z = [M]^+$ C₂1H₃1NO₂ requires 329.2355, found 329.2353.

4.3.3 (3S,4aR,8aR)-Ethyl 1-((R)-1-phenylethyl)decahydroquinoline-3-carboxylate 7c. Using general method B octahydroquinline 6f (0.323 g, 1.03 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* 7c (0.235 g, 72%) as a yellow oil. [α]_D²⁰ +45 (c 1.0, CHCl₃); R_F = 0.75 (1:1 n-hexanes, ethyl acetate); v_{max}/cm^{-1} 2973, 2930, 2870, 1720, 1449, 1367, 1324, 1186, 1153, 1029; δ_H (400 MHz; CDCl₃), 1.14-1.22 (1H, m, H_A-8), 1.9 (3H, t, J = 7.2 Hz, OCH₂CH₃), 1.27-1.30 (3H, m, NCH(CH₃)Ph), 1.32-1.46 (2H, m, H-6), 1.43-1.77 (6H, m, H-4, H-5, H-7), 1.79-1.86 (1H, m, H-4a), 2.00-2.08 (1H, m, H_B-8), 2.40-2.53 (2H, m, H_A-2, H-3), 2.64 (1H, d, J = 5.6 Hz, H_B-2), 3.05 (1H, dt, J = 3.5, 12.0 Hz, H-8a), 3.66 (1H, q, J = 6.4 Hz, NCH(CH₃)Ph), 4.01-4.05 (2H, m, OCH₂CH₃), 7.21-7.35 (5H, m, Ar-H); δ_C (100 MHz; CDCl₃) 14.1 (OCH₂CH₃), 18.0 (NCH(CH₃)Ph), 21.0 (C-7), 22.2 (C-6), 25.6 (C-8), 27.6 (C-4), 31.6 (C-5), 34.7 (C-4a), 42.3 (C-3), 45.4 (C-2), 55.1 (NCH(CH₃)Ph), 60.0 (C-8a), 60.4 (OCH₂CH₃), 126.5 (Ar-CH), 126.9 (Ar-CH), 128.3 (Ar-CH), 147.1 (Ar-C), 174.8 (COO); HRMS (EI+) m/z = [M]⁺ C₂₀H₂₉NO₂ requires 315.21983; found 315.21981.

4.3.4 $(3S^*,4aR^*,9aR^*)$ -Ethyl 1-benzyldecahydro-1H-cyclohepta[b]pyridine-3-carboxylate **7d**. Using general method B octahydroquinline **6c** (0.600 g, 1.91 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* **7d** (0.357 g, 58%) as a yellow oil. $R_F = 0.7$ (4:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2923, 2853, 1728, 1454, 1255, 1148; δ_H (400 MHz; CDCl₃) 0.97-1.08 (1H, m, H_A-5), 1.02-1.15 (1H, m, H_A-4), 1.11-1.22 (1H, m, H_A-6 or H_A-7), 1.22-1.32 (1H, m, H_A-8), 1.23 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.34-1.47 (2H, m, H_B-6- or H_B-7 and H_A-9), 1.52-1.60 (1H, m, H_B-8), 1.64-1.73 (1H, m, H_B-9), 1.73-1.86 (3H, m, H_B-4 and H-6 or H-7), 1.88-1.97 (1H, m, H_B-5), 2.37-2.48 (1H, m, H_A-2), 2.54-2.61 (1H, m, H-3), 2.65-2.73 (1H, m, H_B-2), 2.69-2.84 (1H, m, H-9a), 3.59-3.70 (2H, m, NCH₂Ph), 4.03-4.13 (2H, m, OCH₂CH₃), 7.14-7.37 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 14.2 (OCH₂CH₃), 20.2 (C-9), 23.3 (C-8), 28.1 (C-4), 31.0, 31.1 (C-6, C-7), 33.5 (C-5), 36.8 (C-4a), 42.3 (C-3), 47.7 (C-2), 58.9 (NCH₂Ph), 60.1 (OCH₂CH₃), 62.2 (C-9a), 126.7 (Ar-CH), 128.1 (Ar-CH), 128.3 (Ar-CH), 139.7 (Ar-C), 174.6 (COO); HRMS (EI+) $m/z = [MH]^+$ $C_{20}H_{30}NO_2$ requires 316.2271; found 316.2262.

4.3.5 (3 S^* ,4a R^* ,9a R^*)-Ethyl 1-(3-phenylpropyl)decahydro-1H-cyclohepta[b]pyridine-3-carboxylate **7e**. Using general method B octahydroquinline **6i** (0.350 g, 1.02 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* **7e** (0.188 g, 54%) a yellow oil; $R_F = 0.6$ (3:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2931, 2850, 1721, 1451, 1247, 1155, 1031; δ_H (400 MHz; CDCl₃) 0.96-1.07 (1H, m, H_A-5), 1.11-1.20 (2H, m, H_A-4 and H_A-6 or H_A-7), 1.23 (3H, t, J = 7.2 Hz, OCH₂CH₃), 1.29-1.40 (3H, m, H_A-8, H_A-9 and H_A-6 or H_A-7), 1.51-1.65 (2H, m, H_B-8, H_B-9), 1.73-1.85 (4H, m, NCH₂CH₂CH₂Ph, H_B-6, H_B-7), 1.90-2.02 (2H, m, H-4a, H_B-5), 2.32 (1H, t, J = 12.1 Hz, H_A-2), 2.48 (1H, td, J = 2.2, 7.4 Hz, NCH₂CH₂CH₂Ph), 2.53-2.59 (1H, m, H-3), 2.63 (2H, t, J = 7.4 Hz, NCH₂CH₂CH₂Ph), 2.73-2.77 (1H, m, H_B-2), 2.78-2.82 (1H, m, H-9a), 4.06-4.12 (2H, m, OCH₂CH₃), 7.13-7.29 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 14.1 (OCH₂CH₃), 19.6 (C-9), 23.1 (C-8), 28.1 (C-4), 29.4 (NCH₂CH₂CH₂Ph), 30.8, 31.0 (C-6, C-7), 33.4, 33.5 (C-5, NCH₂CH₂CH₂Ph), 36.4 (C-4a), 42.0 (C-3), 48.1 (C-2), 53.6 (NCH₂CH₂CH₂Ph), 60.0 (OCH₂CH₃), 61.8 (C-9a), 125.5 (Ar-CH), 128.1 (Ar-CH), 128.3 (Ar-CH), 142.2 (Ar-C), 174.4 (COO); HRMS (EI+) $m/z = [MH]^+$ C₂₂H₃₄NO₂ requires 344.2584; found 344.2578.

4.3.6 (3S,4aR,9aR)-Ethyl 1-((R)-1-phenylethyl)decahydro-1H-cyclohepta[b]pyridine-3-carboxylate 7f. Using general method B octahydroquinline 6j (0.236 g, 0.721 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* 7f (0.123 g, 52%) as a pale yellow oil. [α]_D²⁰ +68 (*c* 1.0, CHCl₃); $R_F = 0.55$ (3:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2934, 2851, 1725, 1441, 1257, 1130; δ_H (400 MHz; CDCl₃) 1.00-1.05 (1H, m, H_A-5), 1.16 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.18-1.22 (2H, m, H_A-4 and H_A-6 or H_A-7), 1.25 (3H, d, J = 6.7 Hz, NCH(CH₃)Ph), 1.27-1.33 (1H, m, H_A-8), 1.34-1.41 (1H, m, H_A-6 or H_A-7), 1.56-1.63 (3H, m, H_B-8 and H-9), 1.75-1.84 (3H, m, H_B-4, H_B-6, H_B-7), 1.93-2.07 (1H, m, H_A-2), 2.39-2.45 (1H, m, H-3), 2.55-2.61 (1H, m, H_B-2), 3.15 (1H, q, J = 5.0 Hz, NCH(CH₃)Ph), 3.57-3.63 (1H, m, H-9a), 4.00 (2H, q, J = 4.0 Hz, OCH₂CH₃), 7.16-7.37 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 14.1 (OCH₂CH₃), 20.3 (C-9), 22.5 (NCH(CH₃)Ph), 23.3 (C-8), 27.8 (C-4), 31.3, 31.7 (C-6, C-7), 33.9 (C-5), 36.6 (C-4a), 42.1 (C-3), 46.3 (C-2), 57.7 (NCH(CH₃)Ph), 60.0 (OCH₂CH₃), 61.4 (C-9a), 126.6 (Ar-CH), 127.4 (Ar-CH), 128.3 (Ar-CH), 147.4 (Ar-C), 174.8 (COO); HRMS (EI+) $m/z = [MH]^+ C_{21}H_{32}NO_2$ requires 330.2480; found 330.2483.

4.3.7 $(3S^*,4aS^*,8aR^*)$ -Ethyl 1-benzyl-5,7-dimethyldecahydroquinoline-3-carboxylate **7g**. Using general method B octahydroquinline **6b** (0.215 g, 0.67 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* **7g** (0.091 g, 42%) as a pale yellow oil. $R_F = 0.8$ (4:1 *n*-hexanes, ethyl

acetate); $v_{\text{max}}/\text{cm}^{-1}$ 2968, 2950, 2855, 1714, 1495, 1455, 1368, 1239, 1200, 1160, 1064; δ_{H} (400 MHz; CDCl₃) 0.67-0.77 (1H, m, H_A-6), 0.81 (3H, t, J=6.6 Hz, 5-CH₃), 0.89 (3H, t, J=6.6 Hz, 7-CH₃), 0.99-1.09 (1H, m, H_A-8), 1.18 (3H, t, J=7.2 Hz, OCH₂CH₃), 1.25-1.33 (1H, m, H-4a), 1.42-1.51 (1H, m, H_A-4), 1.72-1.80 (1H, m, H_B-6), 1.84-2.00 (2H, m, H-5 and H_A-2), 2.12-2.23 (3H, m, H_B-4, H-7 and H_B-8), 2.35-2.41 (1H, m, H-8a), 2.59-2.69 (1H, m, H-3), 2.91 (1H, d, J=13.3 Hz, NCH_AH_BPh), 2.95-3.00 (1H, m, H_B-2), 4.00-4.08 (2H, m, OCH₂CH₃), 4.11 (1H, d, J=13.6 Hz, NCH_AH_BPh), 7.19-7.34 (5H, m, Ar-H); δ_{C} (100 MHz, CDCl₃) 14.1 (OCH₂CH₃), 19.7 (7-CH₃), 22.6 (5-CH₃), 26.2 (C-5), 28.5 (C-7), 30.3 (C-4), 37.6 (C-4a), 38.7 (C-8), 43.6 (C-3), 45.2 (C-6), 55.2 (C-2), 56.7 (NCH₂Ph), 60.1 (OCH₂CH₃), 61.7 (C-8a), 126.6 (Ar-CH), 127.8 (Ar-CH), 128.6 (Ar-CH), 140.1 (Ar-C), 174.9 (COO); HRMS (EI+) $m/z=[\text{MH}]^+$ C₂₁H₃₂NO₂ requires 330.2428; found 330.2422.

4.3.8 (3 S^* ,4 aS^* ,8 aR^*)-Ethyl 5,7-dimethyl-1-(3-phenylpropyl)decahydroquinoline-3-carboxylate **7h**. Using general method B octahydroquinline **6g** (0.400 g, 1.13 mmol) after purification by chromatography on basic alumina (2% ethyl acetate in *n*-hexanes) gave *title compound* **7h** (0.174 g, 43%) as a pale yellow oil. $R_F = 0.7$ (3:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 2994, 2866, 1730, 1453, 1182, 1153; δ_H (400 MHz; CDCl₃) 0.58-0.70 (1H, m, H_A-6), 0.77 (3H, d, J = 6.5 Hz, 5-CH₃), 0.84 (3H, d, J = 6.5 Hz, 7-CH₃), 0.83-0.94 (1H, m, H_A-8), 1.14-1.22 (1H, m, H-3), 1.24 (3H, t, J = 7.1 Hz, OCH₂CH₃), 1.39 (1H, td, J = 4.6, 13.3 Hz, NCH₂CH₄H_BCH₂Ph), 1.60-1.90 (5H, m, H-4, H-5, H_B-6, H_B-8), 1.91-2.01 (1H, m, H-7), 2.12-2.20 (1H, m, NCH₂CH₄H_BCH₂Ph), 2.23 (1H, t, J = 11.3 Hz, NCH₄H_BCH₂CH₂Ph), 2.28-2.33 (1H, m, H-8a), 2.34-2.44 (1H, m, H_A-2), 2.47-2.71 (4H, m, H_B-2, H-4a, NCH₂CH₂CH₂Ph), 3.07-3.14 (1H, m, NCH₄H_BCH₂CH₂Ph), 4.10 (2H, q, J = 7.1 Hz, OCH₂CH₃), 7.12-7.32 (5H, m, Ar-CH); δ_C (100 MHz, CDCl₃) 14.2 (OCH₂CH₃), 19.7 (7-CH₃), 22.5 (5-CH₃), 25.4 (C-4), 26.3 (C-5), 28.4 (C-7), 30.0 (NCH₂CH₂CH₂Ph), 33.8 (NCH₂CH₂CH₂Ph), 37.8 (C-4a), 38.2 (C-8), 43.2 (C-3), 45.0 (C-6), 52.0 (C-2), 55.1 (NCH₂CH₂CH₂Ph), 60.0 (C-8a), 60.1 (OCH₂CH₃), 125.7 (CH, Par-CH), 128.2 (Ar-CH), 128.3 (Ar-CH), 142.3 (Ar-C), 174.9 (COO); HRMS (EI+) $m/z = [MH]^+$ C₂₃H₃₆NO₂ requires 358.2741; found 358.2748.

4.4 General Method C: Reduction of esters 7 to alcohols 8. To a solution of lithium aluminium hydride (3.0 mmol) in dry THF (2.0 mL) was added dropwise a solution of ester **7** (1.0 mmol) in dry THF (8.0 mL) and the mixture was stirred for 15 min. The reaction was quenched by the dropwise addition of 5.2 M potassium hydroxide (1.2 mL) and stirring continued for 15 min. The resultant mixture was filtered through Celite and washed with ethyl acetate (40 mL). The volatile solvents were removed *in vacuo* to give the desired alcohol **8**, which was used without further purification.

4.4.1 ((3S*,4aR*,8aR*)-1-Benzyldecahydroquinolin-3-yl)methanol **8a**. Using general method C ester **7a** (0.277 g, 0.964 mmol) gave the *title compound* **8a** (0.195 g, quant.) as a pale yellow oil, which was used without further purification. $R_F = 0.2$ (1:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3352, 3027, 2920, 2852, 1494, 1451, 1369, 1069, 1036, 735, 700; δ_H (400 MHz; CDCl₃) 1.02-1.18 (1H, m, H_A-7), 1.23-1.29 (2H, m, H-6), 1.29-1.39 (2H, m, H-4), 1.48-1.64 (4H, m, H-5, H-8), 1.70-1.77 (1H, m, H_B-7), 1.81-1.92 (1H, m, H-3), 2.01-2.08 (1H, m, H-4a), 2.15-2.21 (1H, m, H_A-2), 2.63 (1H, d, J = 11.4 Hz, H_B-2), 2.72-2.82 (1H, m, H-8a), 3.42-3.45 (2H, m, CH₂OH), 3.58 (1H, dd, J = 2.6, 13.6 Hz, NCH_ACH_BPh), 3.73 (1H, dd, J = 2.6, 13.6 Hz, NCH_ACH_BPh), 7.20-7.34 (5H, m, Ar-H); δ_C (100 MHz; CDCl₃) 17.5 (C-8), 20.8 (C-6), 25.4 (C-7), 27.0 (C-4), 31.5 (C-5), 34.9 (C-4a), 39.0 (C-3), 48.6 (C-2), 58.4 (NCH₂Ph), 59.1 (C-8a), 66.1 (CH₂OH), 126.5 (Ar-CH), 128.1 (Ar-CH), 128.4 (Ar-CH), 139.6 (Ar-C); HRMS (EI+) $m/z = [M]^+$ C₁₇H₂₅NO requires 258.20275; found 258.20298.

 $4.4.2~((3S^*,4aR^*,8aR^*)-1-(3-Phenylpropyl)decahydroquinolin-3-yl)methanol$ **8b**. Using general method C ester **7b** (0.350 g, 1.07 mmol) gave *title compound* **8b** (0.130 g, quant.) as a pale yellow oil, which was used without further purification. $R_F = 0.25~(1:1~n\text{-hexanes}, \text{ ethyl acetate}); \nu_{\text{max}}/\text{cm}^{-1} 3444, 3025, 2923, 2853, 1495, 1449, 1371, 1080, 1043, 730, 698; <math>\delta_H$ (300 MHz; CDCl₃) 1.10-1.20 (1H, m, H_A-7), 1.29-1.37 (2H, m, H-4), 1.39-1.42 (2H, m, H-6), 1.43-1.50 (2H, m, H-8), 1.58-1.62 (2H, m, H-5), 1.78-1.82 (1H, m, H_B-7), 1.85-1.93 (3H, m, H-3, NCH₂CH₂CH₂Ph), 1.94-2.08 (1H, m, H-4a), 2.12-2.19 (1H, m, H_A-2), 2.40-2.54 (2H, m, NCH₂CH₂CH₂Ph), 2.55-2.71 (2H, m, NCH₂CH₂CH₂Ph), 2.74-2.76 (1H, m, H_B-2), 2.79-2.81 (1H, m, H-8a), 3.41-3.55 (2H, m, CH₂OH) 7.22-7.35 (5H, m, Ar-H); δ_C (75.5 MHz; CDCl₃) 17.0 (C-8), 21.0 (C-6), 25.6 (C-7), 27.2 (C-4), 29.4 (NCH₂CH₂CH₂Ph), 31.7 (C-5), 33.8 (NCH₂CH₂CH₂Ph), 35.2 (C-4a), 39.4 (C-3), 49.5 (C-2), 53.7 (NCH₂CH₂CH₂Ph), 58.8 (C-8a), 66.41 (CH₂OH), 125.6 (Ar-CH), 128.2 (Ar-CH), 128.3 (Ar-CH), 142.3 (Ar-C); MS (EI): $m/z = 287~(M^+, 32), 244~(97), 182~(100), 91~(27), 44~(21);$); HRMS (EI+) $m/z = [\text{MH}]^+ \text{C}_{21}\text{H}_{29}\text{NO}_2 \text{C}_{19}\text{H}_{29}\text{NO}_2 \text{ requires } 287.2249; \text{ found } 287.2248.$

4.4.3 ((3S,4aR,8aR)-1-((R)-1-Phenylethyl)decahydroquinolin-3-yl)methanol **8c**. Using general method C ester **7c** (0.235 g, 0.740 mmol) gave **8c** (0.202 g, quant.) as a pale yellow solid, which was used without further purification. [α]_D²⁰ +44 (c 1.0, CHCl₃); m.p. 109-110 °C; R_F = 0.15 (1:1 n-hexanes, ethyl acetate); v_{max}/cm⁻¹ 3285, 3027, 2920, 2871, 1450, 1368, 1070, 1040, 761, 701; δ_H (400 MHz; CDCl₃) 1.11-1.22 (1H, m, H_A-7), 1.27 (3H, t, J = 7.4 Hz, NCH(CH₃)Ph), 1.30-1.43 (4H, m, H-4, H-6), 1.46-1.63 (4H, m, H-5, H-8), 1.65-1.78 (1H, m, H_B-7), 1.95-2.08 (3H, m, H_A-2, H-3, H-4a), 2.46 (1H, dd, J = 3.8, 11.6 Hz, H_B-2), 3.08-3.12 (1H, m, H-8a), 3.35 (2H, d, J = 6.0 Hz, CH₂OH), 3.61 (1H, q, J = 6.5 Hz, NCH(CH₃)Ph), 7.17-7.31 (5H, m, Ar-H); δ_C (100 MHz; CDCl₃) 17.6 (C-8), 21.1 (NCH(CH₃)Ph), 22.1 (C-6), 25.9 (C-7), 27.5 (C-4), 31.9 (C-5), 35.2 (C-4a), 39.3 (C-3), 47.1 (C-2), 55.6 (NCH(CH₃)Ph), 60.7 (C-8a), 66.6 (CH₂OH), 126.5 (Ar-CH), 127.0 (Ar-CH), 128.3 (Ar-CH), 147.4 (Ar-C); HRMS (EI+) m/z = [M]⁺ C₁₈H₂₇NO₂ requires 273.21533; found 273.21513.

4.4.4 ((3 S^* ,4a R^* ,9a R^*)-1-Benzyldecahydro-1H-cyclohepta[b]pyridin-3-yl)methanol **8d**. Using general method C ester **7d** (0.147 g, 0.466 mmol) gave *title compound* **8d** (0.127 g, quant.) as a pale yellow oil, which was used without further purification. $R_F = 0.1$ (2:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3336, 2917, 2851, 1453, 1355, 1063, 1026; δ_H (400 MHz; CDCl₃) 0.93-1.06 (4H, m, H-5 and H-6 or H-7), 1.26-1.33 (1H, m, H_A-8), 1.33-1.41 (1H, m, H_A-9), 1.52-1.61 (1H, m, H_B-8), 1.54-1.61 (1H, m, H_A-6 or H_A-7), 1.64-1.71 (1H, m, H_B-9), 1.74-1.80 (1H, m, H_B-6 or H_B-7), 1.76-1.84 (2H, m, H-4), 1.80-1.89 (1H, m, H-3), 2.01-2.07 (1H, m, H_A-2), 2.02-2.11 (1H, m, H-4a), 2.55-2.62 (1H, m, H_B-2), 2.75-2.83 (1H, m, H-9a), 3.38-3.48 (2H, m, NCH₂Ph), 3.62 (2H, q, *J* = 7.6 Hz, CH₂OH), 7.18-7.44 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 20.1 (C-9), 23.4 (C-8), 28.2 (C-4), 31.2, 31.3 (C-6, C-7), 33.9 (C-5), 37.1 (C-4a), 39.2 (C-3), 49.3 (C-2), 59.2 (NCH₂Ph), 62.9 (C-9a), 66.7 (CH₂OH), 126.6 (Ar-CH), 128.1 (Ar-CH), 128.5 (Ar-CH), 140.3 (Ar-C);); HRMS (EI+) $m/z = [MH]^+$ C₁₈H₂₈NO requires 274.2165; found 247.2162.

4.4.5 ((3 S^* ,4 aR^* ,9 aR^*)-1-(3-Phenylpropyl)decahydro-1H-cyclohepta[b]pyridin-3-yl)methanol **8e**. Using general method C ester **7e** (0.160 g, 0.465 mmol) gave *title compound* **8e** (0.125 g, quant.) as a yellow oil, which was used without further purification. $R_F = 0.3$ (1:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3344, 2920, 2852, 1453, 1373, 1105, 1029; δ_H (400 MHz; CDCl₃) 0.88-1.02 (3H, m, H_A-5, and H-6 or H-7), 1.10-1.20 (1H, m, H_A-4), 1.22-1.38 (3H, m, H_B-4, H_A-8, H_A-9), 1.48-1.62 (4H, m, H_B-8, H_B-9 and H-6 or H-7), 1.73-1.84, 1.73-1.84 (3H, m, H-3, NCH₂CH₂CH₂Ph), 1.88-2.02 (3H, m, H_A-2, H-4a, H_B-5), 2.46 (2H, t, J = 7.7 Hz, NCH₂CH₂CH₂Ph), 2.58-2.68 (3H, m, H_B-2, NCH₂CH₂CH₂Ph), 2.79-2.86 (1H, m, H-9a), 3.35-3.50 (2H, m, CH₂OH), 7.14-7.31 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 19.3 (C-9), 23.3 (C-8), 28.3 (C-4), 29.5 (NCH₂CH₂CH₂Ph), 31.1, 31.3 (C-6, C-7), 33.8 (C-5, NCH₂CH₂CH₂Ph), 37.0 (C-4a), 39.1 (C-3), 50.0 (C-2), 54.1 (NCH₂CH₂CH₂Ph), 62.2 (C-9a), 66.5 (CH₂OH), 125.6 (Ar-CH), 128.2 (Ar-CH), 128.4 (Ar-CH), 142.4 (Ar-C); HRMS (EI+) $m/z = [MH]^+$ C₂₀H₃₂NO requires 302.2478; found 302.2483.

4.4.6 ((3S,4aR,9aR)-1-((R)-1-Phenylethyl)decahydro-1H-cyclohepta[b]pyridin-3-yl)methanol **8f**. To Using general method C ester **7f** (0.100 g, 0.30 mmol) gave *title compound* **8f** (0.086 g, quant.) as a pale yellow oil, which was used without further purification. [α]_D²⁰ +72 (c 1.0, CHCl₃); $R_F = 0.2$ (1:1 n-hexanes, ethyl acetate); v_{max}/cm^{-1} 3331, 2929, 2842, 1451, 1347, 1063, 1011; δ_H (400 MHz; CDCl₃) 0.94-1.09 (2H, m, H_A-5 and H_A-6 or H_A-7), 1.23-1.31 (4H, m, H_A-4, NCH(CH₃)Ph), 1.36-1.45 (2H, m, H_A-8, H_A-9), 1.53-1.71 (4H, m, H-3, H_B-8, H_B-9 and H_B-6 or H_B-7), 1.78-1.89 (4H, m, H_A-2, H_B-4, and H-6 or H-7), 1.94-2.02 (1H, m, H_B-5), 2.04-2.11 (1H, m, H-4a), 2.41-2.47 (1H, m, H_B-2), 3.18 (1H, q, J = 5.0 Hz, NCH(CH₃)Ph), 3.31 (2H, dd, J = 1.6, 6.1 Hz, CH₂OH), 3.56-3.36 (1H, m, H-9a), 7.16-7.34 (5H, m, Ar-H); δ_C (100 MHz, CDCl₃) 19.8 (C-9), 22.2 (NCH(CH₃)Ph), 23.4 (C-8), 27.8 (C-4), 31.3, 31.8 (C-6, C-7), 34.3 (C-5), 37.1 (C-4a), 39.0 (C-3), 47.8 (C-2), 58.1 (NCH(CH₃)Ph), 61.3 (C-9a), 66.6 (CH₂OH), 126.5 (Ar-CH), 127.3 (Ar-CH), 128.4 (Ar-CH), 147.6 (Ar-C); HRMS (EI+) m/z = [MH]⁺ C₁₉H₃₀NO requires 288.2322; found 288.2321.

4.4.7 ((3 S^* ,4 aS^* ,8 aR^*)-1-Benzyl-5,7-dimethyldecahydroquinolin-3-yl)methanol **8g**. Using general method C ester **7g** (0.08 g, 0.24 mmol) gave *title compound* **8g** (0.069 g, quant.) as a pale yellow oil, which was used without further purification. $R_F = 0.18$ (1:1 n-hexanes, ethyl acetate); v_{max}/cm^{-1} 3303, 2918, 2860, 1494, 1375, 1121, 1015; δ_H (400 MHz; CDCl₃) 0.65-0.76 (1H, m, H_A-6), 0.81 (3H, d, J = 6.7 Hz, 5-CH₃), 0.86 (3H, d, J = 6.7 Hz, 7-CH₃), 0.96-1.11 (2H, m, H_A-4 and H_A-8), 1.21-1.23 (1H, m, H-3), 1.46-1.54 (1H, m, H_A-2), 1.70-1.77 (1H, m, H_B-6), 1.81-1.96 (3H, m, H-4a, H_B-4, H-5), 2.12-2.22 (2H, m, H-7, H_B-8), 2.27-2.31 (1H, m, H-8a), 2.86-2.93 (2H, m, H_B-2, NCH_AH_BPh), 3.21-3.32 (2H, m, CH₂OH), 4.10 (1H, d, J = 13.6 Hz, NCH_AH_BPh), 7.16-7.37 (5H, m, Ar-CH); δ_C (100 MHz, CDCl₃) 19.6 (7-CH₃), 22.6 (5-CH₃), 26.2 (C-5), 28.8 (C-7), 30.3 (C-4), 34.0 (C-4a), 38.9 (C-8), 43.9 (C-3), 45.3 (C-6), 57.0 and 57.1 (C-2, NCH₂Ph), 62.1 (C-8a), 66.8 (CH₂OH),

- 4.4.8 ((3S*,4aS*,8aR*)-5,7-Dimethyl-1-(3-phenylpropyl)decahydroquinolin-3-yl)methanol **8h**. Using general method C ester **7h** (0.084 g, 0.24 mmol) gave *title compound* **8h** (0.072 g, quant.) as a pale yellow oil, which was used without further purification. $R_F = 0.25$ (1:1 *n*-hexanes, ethyl acetate); v_{max}/cm^{-1} 3318, 2918, 2868, 1453, 1375, 1114, 1076, 1038; δ_H (400 MHz; CDCl₃) 0.56-0.66 (1H, m, H_A-6), 0.78 (3H, d, J = 6.5 Hz, 5-CH₃), 0.82 (3H, d, J = 6.5 Hz, 7-CH₃), 0.83-0.94 (2H, m, H_A-8, NCH₂CH₄H_BCH₂Ph), 1.11-1.19 (1H, m, H-3), 1.62-1.91 (7H, m, H-4, H-4a, H-5, H_B-8, NCH₄H_BCH₂CH₂Ph, NCH₂CH₄H_BCH₂Ph), 1.94-2.03 (1H, m, H-7), 2.25-2.30 (1H, m, H-8a), 2.37-2.70 (4H, m, H-2, NCH₂CH₂CH₂Ph), 3.00-3.06 (1H, m, NCH₄H₂CH₂CH₂Ph), 3.28-3.46 (2H, m, CH₂OH), 7.13-7.29 (5H, m, Ar-CH); δ_C (100 MHz, CDCl₃) 19.7 (7-CH₃), 22.5 (5-CH₃), 25.0 (C-4), 26.3 (C-5), 28.7 (C-7), 30.1 (NCH₂CH₂CH₂Ph), 33.8 (NCH₂CH₂CH₂Ph), 34.4 (C-4a), 38.2 (C-8), 43.5 (C-3), 45.0 (C-6), 52.4 (C-2), 57.0 (NCH₂CH₂CH₂Ph), 60.5 (C-8a), 66.9 (CH₂OH), 125.6 (Ar-CH), 128.2 (Ar-CH), 128.3 (Ar-CH), 142.3 (Ar-C); HRMS (EI+) $m/z = [MH]^+ C_{21}H_{34}NO$ requires 316.2635; found 316.2647.
- **4.5 General Method D: Preparation of anthranilate esters 10.** To a solution of alcohol $\bf 8$ (1.0 mmol) in dry dichloromethane (15 mL) was added acid $\bf 9$ (2.0 mmol), DMAP (0.1 mmol) and DCC (2.0 mmol) and the mixture was stirred for 18 h. The mixture was filtered through Celite and washed with ethyl acetate (90 mL). The filtered mixture was washed with aqueous NaHCO₃ (2 × 90 mL), dried (Na₂SO₄) and the volatile solvents were removed *in vacuo* to give the crude product which was purified by flash column chromatography to give the desired anthranilate ester $\bf 10$.
- 4.5.1 ((3"S*,4a"R*,8a"R*)-1"-Benzyldecahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl)benzoate 10a. Using general method D alcohol 8a (0.080 g, 0.310 mmol) after purification by flash chromatography (20% *n*-hexanes in ethyl acetate) gave *title compound* 10a (0.077 g, 53%) as a green oil. $R_F = 0.7$ (4:1 ethyl acetate, *n*-hexanes,); v_{max}/cm^{-1} 3025, 2929, 1727, 1714, 1602, 1494, 1454, 1393, 1292, 1259, 1108; δ_H (400 MHz; CDCl₃) 1.04-1.14 (1H, m, H_A-7"), 1.26-1.31 (2H, m, H-6"), 1.34-1.43 (2H, m, H-4"), 1.46-1.61 (4H, m, H-5", H-8"), 1.69-1.79 (1H, m, H_B-7"), 1.87-1.94 (1H, m, H-3"), 1.97-2.10 (4H, m, H-4a", 3'-CH₃), 2.22 (1H, t, J = 11.2 Hz, H_A -2"), 2.58 (1H, dd, J = 3.2, 11.2 Hz, H_B -2"), 2.73-2.78 (1H, m, H-8a"), 3.58 (1H, d, J = 13.6 Hz, NCH_AH_BPh), 3.73 (1H, d, J = 13.6 Hz, NCH_AH_BPh), 4.01-4.14 (2H, m, CH₂O), 6.45 (1H, s, H-4'), 7.21-7.34 (6H, m, H-6, Ar-H), 7.44 (1H, t, J = 8.0 Hz, H-5), 7.61 (1H, t, J = 8.0 Hz, H-4), 7.95 (1H, d, J = 8.0 Hz, H-3); δ_C (100 MHz; CDCl₃) 11.1 (3'-CH₃), 17.6 (C-8"), 20.94 (C-6"), 25.4 (C-7"), 27.3 (C-4"), 31.5 (C-5"), 35.0 (C-4a"), 36.1 (C-3"), 48.4 (C-2"), 58.4 (NCH₂Ph), 58.9 (C-8a"), 68.3 (CH₂O), 126.6 (Ar-CH), 127.8 (C-4'), 128.0 (C-1), 128.1 (Ar-CH), 128.5 (Ar-CH), 128.8 (C-5), 130.2 (C-6), 131.4 (C-3), 131.6 (C-2), 133.1 (C-4), 139.7 (Ar-C), 146.1 (C-3'), 164.7 (COO), 169.64 (C-2'), 170.7 (C-5'); HRMS (EI+) $m/z = [M]^+$ C₂₉H₃₂N₂O₄ requires 427.23621; found 427.23547.
- 4.5.2 ((3"S*,4a"R*,8a"R*)-1"-(3-Phenylpropyl)decahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl) **10b**. Using general method D alcohol **8b** (0.112 g, 0.390 mmol) after purification by flash chromatography (20% *n*-hexanes in ethyl acetate) gave *title compound* **10b** (0.180 g, 95%) as a dark green oil. $R_F = 0.65$ (4:1 ethyl acetate, *n*-hexanes,); v_{max}/cm^{-1} 3028, 2927, 1727, 1715, 1600, 1494, 1398, 1290, 1106; δ_H (400 MHz; CDCl₃) 1.03-1.1.17 (1H, m, H_A-7"), 1.29-1.40 (4H, m, H-4", H-6"), 1.41-1.50 (2H, m, H-8"), 1.54-1.59 (2H, m, H-5"), 1.68-1.84 (3H, m, H_B-7", NCH₂CH₂CH₂Ph), 1.98-2.09 (2H, m, H-3", H-4a"), 2.10-2.20 (4H, m, H_A-2", 3'-CH₃), 2.44-2.57 (2H, m, NCH₂CH₂CH₂Ph), 2.61-2.65 (3H, m, H_B-2", NCH₂CH₂CH₂Ph), 2.76-2.80 (1H, m, H-8a"), 4.04-4.21 (2H, m, CH₂O), 6.48 (1H, t, J = 1.7 Hz, H-4'), 7.15-7.30 (6H, m, H-6, Ar-H), 7.49 (1H, dt, J = 1.2, 7.8 Hz, H-5), 7.61 (1H, dt, J = 1.2, 7.8 Hz, H-4), 8.07 (1H, dd, J = 1.2, 7.8 Hz, H-3); δ_C (100 MHz; CDCl₃) 11.1 (3'-CH₃), 16.9 (C-8"), 20.9 (C-6"), 25.5 (C-7"), 27.3 (C-4"), 29.4 (NCH₂CH₂CH₂Ph), 31.5 (C-5"), 33.7 (NCH₂CH₂CH₂Ph), 35.1 (C-4a"), 36.1 (C-3"), 49.1 (C-2"), 53.4 (NCH₂CH₂CH₂Ph), 58.5 (C-8a"), 68.4 (CH₂O), 125.6 (Ar-CH), 127.9 (C-4'), 128.1 (C-1), 128.2 (Ar-CH), 128.3 (Ar-CH), 128.9 (C-5), 130.3 (C-6), 131.5 (C-3), 131.6 (C-2), 133.1 (C-4), 142.3 (Ar-C), 146.2 (C-3'), 164.8 (COO), 169.7 (C-2'), 170.7 (C-5'); HRMS (EI+) $m/z = [M]^+$ C₃₁H₃₆N₂O₄ requires 500.26751; found 500.26752.
- 4.5.3 ((3"S,4a"R,8a"R)-1"-((R)-1-Phenylethyl)decahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl)benzoate **10c**. Using general method D alcohol **8c** (0.100 g, 0.360 mmol) after purification by flash chromatography (20% *n*-hexanes in ethyl acetate) gave *title compound* **10c** (0.121 g, 70%) as a green oil. $[\alpha]_D^{20}$ +46 (*c* 1.0, CHCl₃); $R_F = 0.5$ (4:1 ethyl acetate, *n*-hexanes,); v_{max}/cm^{-1} 2931, 2852, 1710,

1602, 1492, 1452, 1394, 1244, 1208, 1109, 1108; $\delta_{\rm H}$ (400 MHz; CDCl₃) 1.01-1.19 (1H, m, H_A-7"), 1.22-1.26 (3H, m, NCH(CH₃)Ph), 1.29-1.44 (4H, m, H-4", H-6"), 1.52-1.63 (4H, m, H-5", H-8"), 1.71-1.80 (1H, m, H_B-7"), 1.89-2.08 (3H, m, H_A-2", H-3", H-4a"), 2.13 (3H, s, 3'-CH₃), 2.52 (1H, d, J=9.2 Hz, H_B-2"), 3.10-3.17 (1H, m, H-8a"), 3.61 (1H, q, J=6.5 Hz, NCH(CH₃)Ph), 3.82-2.87 (1H, m, CH_AH_BO), 3.96-4.01 (1H, m, CH_AH_BO), 6.45-6.46 (1H, m, H-4'), 7.21-7.39 (7H, m, H-5, H-6, Ar-H), 7.56-7.65 (2H, m, H-3, H-4); $\delta_{\rm C}$ (100 MHz; CDCl₃) 11.0 (3'-CH₃), 17.4 (C-8"), 20.9 (C-6"), 21.0 (NCH(CH₃)Ph), 25.5 (C-7"), 27.4 (C-4"), 31.7 (C-5"), 35.2 (C-4a"), 36.2 (C-3"), 47.0 (C-2"), 55.3 (NCH(CH₃)Ph), 60.5 (C-8a"), 70.0 (CH₂O), 126.5 (Ar-CH), 127.0 (C-4'), 127.8 (C-1), 127.9 (Ar-CH), 128.2 (Ar-CH), 128.8 (C-5), 130.1 (C-6), 131.2 (C-3), 131.6 (C-2), 132.9 (C-4), 146.0 (C-3', Ar-C), 164.44 (COO), 169.4 (C-2'), 170.7 (C-5'); HRMS (EI+) $m/z=[{\rm M}]^+$ $C_{30}H_{34}N_2O_4$ requires 486.25186; found 486.25221.

4.5.4 $((3''S^*,4a''R^*,9a''R^*)-1''$ -Benzyldecahydro-1I-cyclohepta[b]pyridin-3''-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1I-pyrrol-1'-yl)benzoate **10d**. Using general method D alcohol **8d** (0.120 g, 0.44 mmol) after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound **10d** (0.167 g, 78%) as a light green oil. $R_F = 0.55$ (3:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2930, 1715, 1497, 1453, 1371, 1260, 1072; δ_H (400 MHz; CDCl₃) 0.94-1.19 (4H, m, H_A-4", H_A-5", H_A-6", H_A-7"), 1.21-1.30 (1H, m, H_A-8"), 1.31-1.40 (1H, m, H_A-9"), 1.50-1.61 (2H, m, H_B-6"or H_B-7"and 8"-H_B), 1.62-1.70 (1H, m, H_B-9"), 1.71-1.81 (2H, m, H_B-4" and H_B-6" or H_B-7"), 1.85-1.94 (1H, m, H_B-5"), 1.95-2.00 (3H, m, H_A-2", H-3", H-4a"), 2.15 (3H, s, 3'-CH₃), 2.56 (1H, d, J = 9.2 Hz, H_B-2"), 2.77-2.83 (1H, m, H-9a"), 3.58-3.69 (2H, m, NCH₂Ph), 3.91-4.05 (2H, m, CH₂O), 6.44 (1H, s, H-4'), 7.19-7.35 (6H, m, H-6, Ar-H), 7.44 (1H, td, J = 1.4, 7.5 Hz, H-5), 7.61 (1H, td, J = 1.4, 7.5 Hz, H-4), 7.93 (1H, dd, J = 1.4, 7.5 Hz, H-3); δ_C (100 MHz, CDCl₃) 11.1 (3'-CH₃), 19.8 (C-9"), 23.3 (C-8"), 28.0 (C-4"), 31.1, 31.4 (C-6", C-7"), 33.7 (C-5"), 36.0 (C-4a"), 37.0 (C-3"), 49.1 (C-2"), 58.8 (NCH₂Ph), 62.1 (C-9a"), 68.1 (CH₂O), 126.6 (Ar-CH), 127.8 (C-1), 128.1 (2 × Ar-CH), 128.5 (C-4'), 128.8 (C-5), 130.2 (C-6), 131.4 (C-3), 131.5 (C-2), 133.0 (C-4), 139.5 (Ar-C), 146.1 (C-3'), 164.7 (COO), 169.6 (C-2'), 170.7 (C-5'); HRMS (EI+) m/z = [MH]⁺ $C_{30}H_{35}N_2O_4$ requires 487.2591; found 487.2580.

4.5.5 $((3''S^*, 4a''R^*, 9a''R^*)$ -1"-(3-Phenylpropyl)decahydro-1H-cyclohepta[b]pyridin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl)benzoate **10e**. Using general method D alcohol **8e** (0.120 g, 0.40 mmol) after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave *title compound* **10e** (0.136 g, 64%) as a green oil. $R_F = 0.45$ (1:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2928, 2853, 1709, 1585, 1449, 1256, 1134, 1085; δ_H (400 MHz; CDCl₃) 0.93-1.04 (3H, m, H_A-5" and H-6" or H-7"), 1.13-1.19 (2H, m, H-4"), 1.23-1.40 (2H, m, H_A-8", H_A-9"), 1.50-1.62 (4H, m, H_B-8", H_B-9", and H-6" or H-7"), 1.74-1.84 (2H, m, NCH₂CH₂CH₂Ph), 1.90-2.03 (4H, m, H_A-2", H-3", H-4a", H_B-5"), 2.16 (3H, s, 3'-CH₃), 2.46 (2H, t, J = 7.4 Hz, NCH₂CH₂CH₂Ph), 2.57 (1H, d, J = 7.4 Hz, H_B-2"), 2.63 (2H, t, J = 7.3 Hz, NCH₂CH₂CH₂Ph), 2.80-2.86 (1H, m, H-9a"), 3.97-4.07 (2H, m, CH₂O), 6.47 (1H, s, H-4'), 7.16-7.32 (6H, m, H-6, Ar-H), 7.50 (1H, td, J = 1.3, 7.7 Hz, H-5), 7.64 (1H, td, J = 1.3, 7.7 Hz, H-4), 8.06 (1H, dd, J = 1.3, 7.7 Hz, H-3); δ_C (100 MHz, CDCl₃) 11.2 (3'-CH₃), 19.1 (C-9"), 23.3 (C-8"), 28.3 (C-4"), 29.6 (NCH₂CH₂CH₂Ph), 31.2, 31.5 (C-6", C-7"), 33.8 (C-5", NCH₂CH₂CH₂Ph), 36.1 (C-4a"), 37.1 (C-3"), 49.9 (C-2"), 53.9 (NCH₂CH₂CH₂Ph), 61.8 (C-9a"), 68.3 (CH₂O), 125.6 (Ar-CH), 127.9 (C-1), 128.1 (Ar-CH), 128.3 (Ar-CH), 128.4 (C-4'), 128.9 (C-5), 130.1 (C-6), 131.5 (C-3), 131.8 (C-2), 133.3 (C-4), 142.5 (Ar-C), 146.2 (C-3'), 164.9 (COO), 169.6 (C-2'), 170.7 (C-5'); HRMS (EI+) $m/z = [MH]^+$ C₃₂H₃₉N₂O₄ requires 515.2904; found 515.2902.

4.5.6 ((3"S,4a"R,9a"R)-1"-((R)-1-Phenylethyl)decahydro-1H-cyclohepta[b]pyridin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl)benzoate **10f**. Using general method D alcohol **8f** (0.080 g, 0.28 mmol) after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound **10f** (0.122 g, 88%) as a tan oil. [α]_D²⁰ +28 (c 1.0, CHCl₃); $R_F = 0.35$ (1:1 ethyl acetate, n-hexanes,); v_{max} /cm⁻¹ 2929, 1709, 1495, 1451, 1375, 1256, 1083; δ_H (400 MHz; CDCl₃) 1.27 (3H, d, J = 6.7 Hz, NCH(CH₃)Ph), 1.34-1.45 (2H, m, H_A-8", H_A-9"), 1.53-1.68 (4H, m, H-6"or H-7", H_B-8", H_B-9"), 1.79-1.90 (6H, m, H_A-2", H-4", H-4a", H-6" or H-7"), 1.94-2.03 (2H, m, H-5"), 2.04-2.12 (1H, m, H-3"), 2.49 (3H, d, J = 8.3 Hz, 3'-CH₃), 3.21-3.27 (1H, m, NCH(CH₃)Ph), 3.56-3.63 (1H, m, H-9a"), 3.75-3.84 (1H, m, OCH_AH_B), 3.92-3.97 (1H, m, OCH_AH_B), 7.15-7.41 (6H, m, H-4', H-2, H-3, Ar-H), 7.48-7.65 (2H, m, H-4, H-5); δ_C (100 MHz, CDCl₃) 11.2 (3'-CH₃), 19.6 (C-9"), 22.1 (NCH(CH₃)Ph), 23.5 (C-8"), 27.9 (C-4"), 31.4, 31.9 (C-6", C-7"), 34.2 (C-5"), 36.2 (C-4a"), 37.3 (C-3"), 48.0 (C-2"), 57.9 (NCH(CH₃)Ph), 61.2 (C-9a"), 127.8 (Ar-CH), 127.9 (C-4'), 128.0 (Ar-CH) 128.8 (Ar-CH), 129.3 (C-5), 131.4 (C-6), 131.6 (C-3), 133.0 (C-4), 146.1 (C-3', Ar-C), 164.7 (COO), 169.6 (C-2'), 170.6 (C-5'); HRMS (EI+) $m/z = [MH]^+$ C₃₁H₃₇N₂O₄ requires 501.2740; found 501.2748.

4.5.7 ((3"S*, 4a"S*, 8a"R*)-1"-Benzyl-5",7"-dimethyldecahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl)benzoate **10g**. Using general method D alcohol **8g** (0.065 g, 0.23 mmol) after purification by flash chromatography (50% *n*-hexanes in ethyl acetate) gave *title compound* **10g** (0.081 g, 70%) as a light brown oil. $R_F = 0.20$ (1:1 ethyl acetate, *n*-hexanes,); v_{max}/cm^{-1} 2930, 2851, 1718, 1440, 1111; δ_H (400 MHz; CDCl₃) 0.69-0.75 (1H, m, H_A-6"), 0.82 (3H, d, J = 6.6 Hz, 5"-CH₃), 0.85 (3H, d, J = 6.6 Hz, 7"-CH₃), 0.99-1.11 (2H, m, H_A-4" and H_A-8"), 1.24-1.30 (1H, m, H-3"), 1.54-1.61 (1H, m, H_A-2"), 1.71-1.78 (1H, m, H_B-6"), 1.87-2.00 (2H, m, H_B-4" and H-5"), 2.04-2.21 (6H, m, H-4a", H-7", H_B-8", 3'-CH₃), 2.31-2.35 (1H, m, H-8a"), 2.87-2.96 (2H, m, H_B-2", NCH_AH_BPh), 3.80-4.00 (2H, m, CH₂O), 4.08-4.15 (1H, m, NCH_AH_BPh), 6.44 (1H, s, H-4'), 7.16-7.36 (6H, m, H-6, Ar-CH), 7.39 (1H, td, J = 1.5, 7.7 Hz, H-5), 7.60 (1H, td, J = 1.5, 7.7 Hz, H-4), 7.76 (1H, dd, J = 1.5, 7.7 Hz, H-3); δ_C (100 MHz, CDCl₃) 11.3 (3'-CH₃), 19.7 (7"-CH₃), 22.6 (5"-CH₃), 26.2 (C-5"), 28.8 (C-7"), 30.3 (C-4"), 31.1 (C-4a"), 38.7 (C-8"), 44.1 (C-3"), 45.2 (C-6"), 56.8 (C-2", NCH₂Ph), 62.1 (C-8a"), 68.4 (CH₂O), 126.5 (Ar-CH), 127.8 (Ar-CH), 128.0 (C-1), 128.1 (Ar-CH), 128.7 (C-4'), 128.8 (C-5), 130.2 (C-3), 131.5 (C-6), 131.6 (C-2), 133.0 (C-4), 140.0 (Ar-C), 146.1 (C-3'), 164.6 (COO), 169.7 (C-2'), 170.7 (C-5'); HRMS (EI+) $m/z = [MH]^+$ C₃₁H₃₇N₂O₄ requires 501.2748; found 501.2760.

4.5.8 ((3"S*,4a"S*,8a"R*)-5",7"-Dimethyl-1"-(3-phenylpropyl)decahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1H-pyrrol-1'-yl)benzoate 10h. Using general method D alcohol 8h (0.065 g, 0.21 mmol) after purification by flash chromatography (50% n-hexanes in ethyl acetate) gave title compound 10h (0.085 g, 77%) as a pale green oil. $R_F = 0.60 \text{ (2:1 ethyl acetate, } n\text{-hexanes,}); v_{\text{max}}/\text{cm}^{-1} 2935, 2844, 1717, 1438,}$ 1114; $\delta_{\rm H}$ (400 MHz; CDCl₃) 0.63 (1H, q, J = 12.5 Hz, H-6"), 0.77 (3H, d, J = 6.5 Hz, 5"-CH₃), 0.82 (3H, d, J = 6.5 Hz, 7"-CH₃), 0.86-0.94 (1H, m, H_A-8"), 0.97-1.05 (1H, m, NCH₂CH_ACH_BCH₂Ph), 1.15-1.22 (1H, m, H-3"), 1.64-1.74 (2H, m, H-5" and H_B -6"), 1.76-2.03 (6H, m, H-4", H-7", H_B -8", $NCH_2CH_AH_BCH_2Ph$, NCH_AH_BCH₂CH₂Ph), 2.07-2.14 (1H, m, H-4a"), 2.16 (3H, s, 3'-CH₃), 2.28-2.33 (1H, m, H-8a"), 2.40-2.48 (1H, $m, H_A-2"$), 2.49-2.56 (1H, m, NCH₂CH₂CH_AH_BPh), 2.86-2.90 (2H, m, H_B-2", NCH₂CH₂CH_AH_BPh), 3.00-3.04 (1H, m, $NCH_AH_BCH_2CH_2Ph$), 3.90-4.06 (2H, m, CH_2O), 6.50 (1H, s, H-4'), 7.13-7.31 (6H, m, H-6, Ar-CH), 7.45-7.53 (1H, m, H-5), 7.60-7.68 (1H, m, H-4), 8.70 (1H, dd, J=1.5, 7.6 Hz, H-3); δ_{C} (100 MHz, CDCl₃) 11.1 (3'-CH₃), 19.7 (7"-CH₃), 22.5 (5"-CH₃), 25.0 (C-4"), 26.4 (C-5"), 28.7 (C-7"), 30.1 (NCH₂CH₂CH₂Ph), 31.3 (C-4a"), 33.8 (NCH₂CH₂CH₂Ph), 38.2 (C-8"), 43.4 (C-3"), 45.0 (C-6"), 52.2 (C-2"), 57.0 (NCH₂CH₂CH₂Ph), 60.2 (C-8a"), 68.8 (CH₂O), 125.7 (Ar-CH), 127.4 (C-1), 127.8 (Ar-CH), 128.2 (C-4'), 128.3 (Ar-CH), 128.4 (C-5), 128.9 (C-6), 130.3 (C-3), 131.7 (C-2), 133.2 (C-4), 142.3 (Ar-C), 146.4 (C-3'), 164.7 (COO), 169.7 (C-2'), 170.8 (C-5'); HRMS (EI+) $m/z = [MH]^+ C_{31}H_{39}N_2O_4$ requires 529.3061; found 529.3055.

4.6 General Method E: Preparation of succinimido anthranilates 11. To a solution of anthranilate ester **10** (1.0 mmol) in ethyl acetate (15 mL) was added 10% palladium on carbon (60 mg) and the resulting mixture was stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which was washed with ethyl acetate (50 mL) and the volatile solvents were removed *in vacuo* to give the desired succinimide anthranilate **11**.

4.6.1 ((3"S*,4a"R*,8a"R*)-1"-Benzyldecahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate **11a**. Using general method E anthranilate ester **10a** (0.077 g, 0.160 mmol) gave *title compound* **11a** (0.075 g, 97%) as a tan oil. $R_F = 0.7$ (4:1 ethyl acetate, *n*-hexanes,); v_{max}/cm^{-1} 2926, 2853, 1713, 1603, 1493, 1389, 1290, 1259, 1184, 1036, 1082, 1044; δ_H (400 MHz; CDCl₃) 1.05-1.14 (1H, m, H_A-7"), 1.26-1.34 (2H, m, H-6"), 1.36-1.49 (5H, m, H-4", 3'-CH₃), 1.50-1.61 (4H, m, H-5", H-8"), 1.69-1.77 (1H, m, H_B-7"), 1.83-1.97 (1H, m, H-3"), 2.00-2.12 (1H, m, H-4a"), 2.24 (1H, t, J = 11.3 Hz, H_A -2"), 2.42-2.60 (2H, m, H-4'), 2.62-2.65 (1H, m, H_B-2"), 2.72-2.81 (1H, m, H-8a"), 2.98-3.13 (1H, m, H-3'), 3.60 (1H, d, J = 13.4 Hz, NC H_A H_BPh), 3.74 (1H, d, J = 13.4 Hz, NC H_A H_BPh), 3.98-4.25 (2H, m, CH₂O), 7.21-7.36 (6H, m, H-6, Ar-H), 7.46 (1H, dt, J = 1.3, 7.7 Hz, H-5), 7.63 (1H, dt, J = 1.3, 7.7 Hz, H-4), 7.96 (1H, d, J = 10.0 Hz, H-3); δ_C (100 MHz; CDCl₃) 16.2 (3'-CH₃), 16.4 (3'-CH₃*), 17.7 (C-8"), 20.9 (C-6"), 25.4 (C-7"), 27.3 (C-4"), 31.5 (C-5"), 33.9 (C-4-a"), 35.2 (C-3'), 35.5 (C-3') 36.1 (C-3"), 36.9 (C-4'), 48.4 (C-2"), 58.4 (NCH₂Ph), 59.0 (C-8a"), 68.1 (CH₂O), 122.7 (Ar-CH), 127.3 (C-1), 128.1 (Ar-CH), 128.5 (Ar-CH), 129.2 (C-5), 129.7 (C-6), 131.4 (C-3), 132.6 (C-2), 133.2 (C-4), 139.6 (Ar-C), 164.1 (COO), 171.0 (C-2'), 179.8 (C-5'); HRMS (EI+) $m/z = [M]^+$ C₂₉H₃₄N₂O₄ requires 474.25186; found 474.25225.

4.6.2 $((3''S^*,4a''R^*,8a''R^*)-1''-(3-Phenylpropyl)decahydroquinolin-3''-yl)methyl$ 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate **11b**. Using general method E anthranilate ester **10b** (0.180 g, 0.360 mmol) gave *title compound* **11b** (0.172 g, 95%) as a green oil. $R_F = 0.7$ (4:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2928, 2853, 1711, 1602, 1493, 1389, 1184, 1031; δ_H (400 MHz; CDCl₃) 1.02-1.98 (1H, m, H_A-7"), 1.23-1.52 (9H, m, H-4",

H-6", H-8", 3'-CH₃), 1.57-1.62 (2H, m, H-5"), 1.72-1.80 (1H, m, H_B-7"), 1.81-1.92 (2H, m, NCH₂CH₂CH₂Ph), 2.02-2.07 (1H, m, H-4a"), 2.14-2.20 (2H, m, H_A-2", H-3'), 2.47-2.59 (3H, m, H_A-4', NCH₂CH₂CH₂Ph), 2.61-2.65 (2H, m, NCH₂CH₂CH₂Ph), 2.71-2.80 (1H, m, H_B-2"), 2.82-2.93 (1H, m, H-8a"), 2.95-3.14 (2H, m, H-3', H_B-4'), 4.06-4.13 (2H, m, CH₂O), 7.14-7.28 (6H, m, H-6, Ar-H), 7.50 (1H, dt, J = 1.2, 7.7 Hz, H-5), 7.64 (1H, dt, J = 1.2, 7.7 Hz, H-4), 8.07 (1H, d, J = 7.7 Hz, H-3); δ_C (100 MHz; CDCl₃) 16.2 (3'-CH₃), 16.4 (3'-CH₃*), 17.0 (C-8"), 20.9 (C-6"), 25.3 (C-7"), 27.0 (C-4"), 28.7 (NCH₂CH₂CH₂Ph), 31.3 (C-5"), 33.4 (NCH₂CH₂CH₂Ph), 34.6 (C-4a"), 35.0 (C-3'), 35.2 (C-3'), 35.7 (C-3"), 36.8 (C-4'), 48.9 (C-2"), 53.2 (NCH₂CH₂CH₂Ph), 58.4 (C-8a"), 67.9 (CH₂O), 125.6 (Ar-CH), 127.2 (C-1), 128.1 (Ar-CH), 128.2 (Ar-CH), 129.2 (C-5), 129.7 (C-6), 131.3 (C-3), 132.6 (C-2), 133.2 (C-4), 141.9 (Ar-C), 164.2 (COO), 175.8 (C-2'), 179.7 (C-5'); HRMS (EI+) $m/z = [M]^+ C_{31} H_{38} N_2 O_4$ requires 502.28316; found 502.28394.

4.6.3 ((3"S,4a"R,8a"R)-1"-((R)-1-Phenylethyl)decahydroquinolin-3"-yl)methyl2-(3'-methyl-2',5'dioxopyrrolidin-1'-yl)benzoate 11c. Using general method E anthranilate ester 10c (0.100 g, 0.205 mmol) gave title compound 11c (0.095 g, 95%) as a yellow oil. [α]_D²⁰ +30 (c 1.0, CHCl₃); $R_F = 0.5$ (4:1 ethyl acetate, nhexanes,); v_{max}/cm^{-1} 2927, 2840, 1720, 1605, 1494, 1452, 1393, 1245, 1205, 1110, 1108; δ_H (400 MHz; CDCl₃) 1.01-1.13 (1H, m, H_A-7"), 1.17-1.33 (5H, m, H-6", NCH(CH₃)Ph), 1.35-1.46 (5H, m, H-4", 3'-CH₃), 1.51-1.71 $(4H, m, H-5", H-8"), 1.75-1.83 (1H, m, H_B-7"), 1.89-1.92 (1H, m, H-3"), 1.95-2.10 (2H, m, H_A-2", H-4a"),$ 2.44-2.50 (2H, m, H-4'), 2.55 (1H, d, J = 8.8 Hz, H_B-2), 2.95-3.14 (1H, m, H-3'), 3.18-3.21 (1H, m, H-8a"), 3.57-3.68 (1H, q, J = 6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, NCH(CH₃)Ph), 3.83-3.90 (1H, m, CH_AH_BO), 4.00-4.07 (1H, m, CH_AH_BO), 7.19-6.8 Hz, 7.11.40 (7H, m, H-5, H-6, Ar-H), 7.58-7.62 (2H, m, H-3, H-4); $\delta_{\rm C}$ (100 MHz; CDCl₃) 16.2 (3'-CH₃), 16.4 (3'-CH₃*), 17.3 (C-8"), 21.0 (NCH(CH₃)Ph), 21.1 (C-6"), 25.5 (C-7"), 27.3 (C-4"), 30.8 (C-5"), 35.1 (C-3"), 35.3 (C-4a"), 36.3 (C-3'), 36.9 (C-4'), 48.8 (C-2"), 55.3 (NCH(CH₃)Ph), 60.5 (C-8a"), 67.9 (CH₂O), 126.4 (Ar-CH), 127.0 (C-1), 128.2 (2 × Ar-CH), 129.2 (C-5), 129.6 (C-6), 131.3 (C-3), 132.6 (C-2), 133.1 (C-4), 147.0 (Ar-C), 163.9 (COO), 171.0 (C-2'), 179.8 (C-5'); HRMS (EI+) $m/z = [M]^+ C_{30}H_{36}N_2O_4$ requires 488.2675; found 488.2677.

4.6.4 $((3"S^*, 4a"R^*, 9a"R^*)-1"$ -Benzyldecahydro-1H-cyclohepta[b]pyridin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate **11d**. Using general method E anthranilate ester **10d** (0.130 g, 0.27 mmol) gave title compound **11d** (0.128 g, 97%) as a tan oil. $R_F = 0.8$ (4:1 ethyl acetate, n-hexanes,); v_{max} /cm⁻¹ 2975, 2918, 1712, 1495, 1389, 1262, 1180, 1080; $δ_H$ (400 MHz; CDCl₃) 0.96-1.05 (1H, m, H_A-5") 1.21 (1H, m, H_A-8"), 1.33-1.41 (1H, m, H_A-9"), 1.46-1.51 (3H, m, 3'-CH₃), 1.51-1.65 (3H, m, H_B-8" and H-6" or H-7"), 1.66-1.73 (1H, m, H_B-9"), 1.74-1.84 (4H, m, H-4" and H-6" or H-7"), 1.88-1.98 (1H, m, H_B-5"), 2.02-2.19 (3H, m, H-4', H_A-2"), 2.45-2.60 (2H, m, H-3', H_B-2"), 2.80-2.87 (1H, m, H-9a"), 3.00-3.15 (2H, m, H-3", H-4a"), 3.60 (2H, s, NCH₂Ph), 3.96-4.10 (2H, m, OCH₂), 7.20-7.39 (6H, m, H-6, Ar-H), 7.45 (1H, t, J = 7.5 Hz, H-5), 7.62 (1H, dt, J = 1.0, 7.5 Hz, H-4), 7.90-7.97 (1H, m, H-3); $δ_C$ (100 MHz, CDCl₃) 16.3 (3'-CH₃), 16.4 (3'-CH₃*), 20.0 (C-9"), 23.4 (C-8"), 28.1 (C-4"), 31.2, 31.5 (C-6", C-7"), 33.8 (C-5"), 35.2 (C-4a"), 36.1 (C-3"), 37.0 (C-4'), 37.1 (C-3'), 49.2 (C-2"), 58.9 (NCH₂Ph), 62.4 (C-9a"), 68.1 (OCH₂), 126.8 (Ar-CH), 127.3 (C-1) 128.2 (Ar-CH), 128.7 (Ar-CH), 129.4 (C-5), 129.8 (C-6), 131.5 (C-3), 132.6 (C-2), 133.3 (C-4), 139.5 (Ar-C), 164.2 (COO), 175.8 (C-2'), 176.0 (C-5'); HRMS (EI+) m/z = [MH]⁺ C₃₀H₃₇N₂O₄ requires 489.2748; found 489.2739.

4.6.6 ((3"S,4a"R,9a"R)-1"-((R)-1-Phenylethyl)decahydro-1H-cyclohepta[b]pyridin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate 11f. Using general method E anthranilate ester 10f (0.09 g, 0.18 mmol) gave title compound 11f (0.089 g, 99%) as a tan oil. [α]_D²⁰ +25 (c 1.0, CHCl₃); $R_F = 0.35$ (1:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2917, 1708, 1452, 1389, 1179, 1079; δ_H (400 MHz; CDCl₃) 0.98-1.04 (2H, m, H_A-5" and H_A-6" or H_A-7"), 1.25-1.32 (3H, m, NCH(CH_3)Ph), 1.35-1.48 (4H, m, 3'-CH₃, H_A-8"), 1.53-1.69 (4H, m, H_B-8", H-9" and H_B-6" or H_B-7"), 1.79-2.14 (7H, m, H_A-2", H-4a", H-4", H_B-5" and H-6" or H-7"), 2.43-2.58 (3H, m, H-4', H_B-2"), 2.95-3.12 (2H, m, H-3', H-3"), 3.22-3.28 (1H, m, NCH(CH_3)Ph), 3.56-3.64 (1H, m, H-9a"), 3.75-3.84 (1H, m, CH_AH_BO), 3.93-4.02 (1H, m, CH_AH_BO), 7.14-7.41 (6H, m, H-6, Ar-H), 7.54-7.64 (3H, m, H-3, H-4, H-5); δ_C (100 MHz, CDCl₃) 16.3 (3'- CH_3), 16.4 (3'- CH_3 *), 19.6 (C-9"), 22.1 (NCH(CH_3)Ph), 23.5 (C-8"), 27.9 (C-4"), 31.4, 31.8 (C-6", C-7"), 34.2 (C-5"), 35.2 (C-3'), 35.4 (C-3'), 36.2 (C-4a"), 37.0 (C-4'), 37.3 (C-3"), 48.1 (C-2"), 57.9 (NCH(CH_3)Ph), 61.3 (C-9a"), 67.9 (CH₂O), 126.5 (Ar-CH), 127.2 (Ar-CH), 127.5 (Ar-CH), 128.3 (Ar-CH), 129.3 (C-5), 129.6 (C-6), 131.4 (C-3), 132.6 (C-2), 133.0 (C-4), 146.7 (Ar-C), 164.0 (COO), 175.7 (C-2'), 175.9 (C-5'); HRMS (EI+) $m/z = [MH]^+ C_{31}H_{39}N_{2}O_4$ requires 503.2904; found 503.2913.

4.6.7 $((3"S^*,4a"S^*,8a"R^*)-1"-Benzyl-5",7"-dimethyldecahydroquinolin-3"-yl)methyl$ 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate **11g**. Using general method E anthranilate ester **10g** (0.07 g, 0.14 mmol) gave title compound **11g** (0.068 g, 97%) as a pale brown oil. $R_F = 0.2$ (1:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2920, 1714, 1495, 1453, 1262, 1197, 1083; δ_H (400 MHz; CDCl₃) 0.67-0.75 (1H, m, H_A-6"), 0.82 (3H, d, J = 6.6 Hz, 5"-CH₃), 0.86 (3H, d, J = 6.6 Hz, 7"-CH₃), 1.00-1.13 (2H, m, H_A-4", H_A-8"), 1.25-1.31 (1H, m, H-3"), 1.38-1.50 (3H, m, 3'-CH₃), 1.55-1.62 (1H, m, H_A-2"), 1.71-1.78 (1H, m, H_B-6"), 1.86-2.00 (2H, m, H_B-4" and H-5"), 2.08-2.23 (3H, m, H-4a", H-7", H_B-8"), 2.32-2.37 (1H, m, H-8a"), 2.43-2.56 (2H, m, H-4'), 2.88-3.11 (3H, m, H_B-2", H-3', NCH_AH_BPh), 3.78-4.00 (2H, m, CH₂O), 4.09-4.16 (1H, m, NCH_AH_BPh), 7.16-7.35 (6H, m, H-6, Ar-CH), 7.39 (1H, bt, J = 7.6 Hz, H-5), 7.60 (1H, bt, J = 7.6 Hz, H-4), 7.75 (1H, bd, J = 7.6 Hz, H-3); δ_C (100 MHz, CDCl₃) 16.1 (3'-CH₃), 16.4 (3'-CH₃*), 19.6 (7"-CH₃), 22.1 (5"-CH₃), 26.1 (C-5"), 28.8 (C-7"), 30.2 (C-4"), 31.0 (C-4a"), 35.1 (C-3'), 35.2 (C-3'), 36.8 (C-4'), 38.6 (C-8"), 43.7 (C-3"), 45.1 (C-6"), 56.8 (C-2", NCH₂Ph), 62.1 (C-8a"), 68.2 (CH₂O), 126.5 (Ar-CH), 127.2 (C-1), 128.1 (Ar-CH), 128.7 (Ar-CH), 129.2 (C-5), 129.6 (C-3), 131.2 (C-6), 132.7 (C-2), 133.1 (C-4), 140.0 (Ar-C), 164.4 (COO), 170.0 (CO), 171.0 (CO); HRMS (EI+) $m/z = [MH]^+$ C_{31} H₃₉N₂O₄ requires 503.2904; found 503.2914.

4.6.8 ((3"S*,4a"S*,8a"R*)-5",7"-Dimethyl-1"-(3-phenylpropyl)decahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate 11h. Using general method E anthranilate ester 10h (0.08 g, 0.15 mmol) gave title compound 11h (0.078 g, 98%) as a pale green oil. $R_F = 0.6$ (2:1 ethyl acetate, *n*-hexanes,); v_{max}/cm^{-1} 2926, 2864, 1710, 1453, 1390, 1259, 1182; δ_H (400 MHz; CDCl₃) 0.64 (1H, q, J = 12.5 Hz, H_A -6"), 0.78 (3H, d, J = 6.5 Hz, 5"-CH₃), 0.83 (3H, d, J = 6.5 Hz, 7"-CH₃), 0.87-0.94 (1H, m, H_A -8"), 1.02 (1H, td, J = 4.6, 13.0 Hz, NCH₂CH_AH_BCH₂Ph), 1.16-1.24 (1H, m, H-3"), 1.42-1.52 (3H, m, 3'-CH₃), 1.61-2.05 (8H, m, H-4", H-5", H_B-6", H-7", H_B-8", NCH₂CH_AH_BCH₂Ph, NCH_AH_BCH₂CH₂Ph), 2.12-2.21 (1H, m, H-4a"), 2.28-2.34 (1H, m, H-8a"), 2.41-2.72 (4H, m, H-2", NCH₂CH₂CH₂Ph), 3.00-3.15 (4H, m, H-3', H-4', NCH_AH_BCH₂CH₂Ph), 3.91-4.08 (2H, m, CH₂O), 7.14-7.32 (6H, m, H-6, Ar-CH), 7.49 (1H, td, J = 1.2, 7.7 Hz, H-5), 7.65 (1H, td, J = 1.2, 7.7 Hz, H-4), 8.09 (1H, d, J = 7.7 Hz, H-3); δ_C (100 MHz, CDCl₃) 16.3 (3'-CH₃), 16.6 (3'-CH₃*), 19.8 (7"-CH₃), 22.6 (5"-CH₃), 26.0 (C-4"), 26.5 (C-5"), 28.8 (C-7"), 30.2 (NCH₂CH₂CH₂Ph), 31.4 (C-4a"), 33.8 (NCH₂CH₂CH₂Ph), 35.1 (C-3'), 35.3 (C-3'), 37.0 (C-4'), 38.3 (C-8"), 43.5 (C-3"), 45.1 (C-6"), 52.3 (C-2"), 57.0 (NCH₂CH₂CH₂Ph), 60.3 (C-8a"), 68.6 (CH₂O), 125.6 (Ar-CH), 127.6 (C-1), 128.2 (Ar-CH), 128.3 (Ar-CH), 129.3 (CH C-5), 129.8 (C-6), 131.4 (C-3), 132.8 (C-2), 133.3 (C-4), 142.3 (Ar-C), 164.5 (COO), 176.0 (C-2'), 179.8 (C-5'); HRMS (EI+) $m/z = [MH]^+$ C₃₃H₄₃N₂O₄ requires 531.3217; found 531.3218.

4.7 Synthesis of succinimido anthranilate 16

4.7.1 (3S,4aR,8aR)-Ethyl 1-acetyldecahydroquinoline-3-carboxylate 13. To a solution of decahydroquinoline 7c (0.342 g, 1.09 mmol) in methanol (5.0 mL) was added 10% palladium on carbon (0.035 g, 0.11 mmol) and the resulting mixture was stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which was washed with ethyl acetate (25 mL) and the volatile solvent were removed *in vacuo* to give (3S,4aR,8aR)-ethyl decahydroquinoline-3-carboxylate 12 (0.208 g, 91%) as a pale green oil which was used immediately without further purification. To a solution of (3S,4aR,8aR)-ethyl decahydroquinoline-3-carboxylate 12 (0.200 g, 0.98 mmol) in dichloromethane (7.0 mL) was added freshly distilled triethylamine (7.0 mL) and the stirred mixture was cooled to 0 °C, DMAP (0.009 g, 0.01 mmol) was added followed by acetic anhydride (0.102 mL, 1.08 mmol) and the mixture was allowed to warm to room temperature and stirred for 20 h. The resultant

mixture was acidified with 2M HCl (40 mL) and the organic layer was separated and the aqueous layer was washed with CH₂Cl₂ (2 × 40 mL). The combined organic extracts were washed with brine (80 mL), dried (Na₂SO₄) and the volatile solvents were removed *in vacuo* to give the *title compound* **13** (0.250 g, quant.) as a pale orange oil which was used without further purification. [α]_D²⁰ +10 (c 1.0, CHCl₃); R_F = 0.15 (1:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2963, 2874, 1714 , 1652, 1363, 1182, 1102; δ_H (400 MHz; CDCl₃) [* denotes signal from minor rotamer] 1.18-1.35 (7H, m, OCH₂CH₃, H-5, H-7), 1.36-1.47 (4H, m, H-5*, H-6), 1.57-1.68 (6H, m, H-6*, H-8, H-8*), 1.68-1.76 (4H, m, H-4*), 1.77-1.85 (3H, m, H-4a, H-7*), 1.86-1.94 (3H, m, H-4*, H-4a*), 2.06 (6H, d, J = 4.1 Hz, COCH₃, COCH₃*), 2.35-2.46 (2H, m, H-2), 2.62 (1H, t, J = 12.4 Hz, H_A-2*), 3.06 (1H, q, J = 7.0 Hz, H_B-2*), 3.14 (1H, t, J = 12.4 Hz, H-3), 3.65 (1H, d, J = 12.0 Hz, H-8a), 3.73 (1H, dd, J = 3.8, 12.4 Hz, H-3*), 4.05-4.16 (4H, m, OCH₂CH₃), OCH₂CH₃*), 4.55-4.63 (1H, m, H-8a*), 4.66-4.73 (1H, m, H_B-2*); δ_C (100 MHz; CDCl₃) 8.5 (OCH₂CH₃), 14.1 (OCH₂CH₃*), 19.7 (C-5), 20.0 (C-5*), 21.5 (COCH₃), 22.1 (COCH₃**), 23.4 (C-6), 24.5 (C-6*), 25.3 (C-7), 25.5 (C-7*), 27.2 (C-4), 27.3 (C-4*), 30.7 (C-8), 30.9 (C-8*), 33.8 (C-4a), 34.8 (C-4a*), 37.2 (C-2), 42.6 (C-2*), 41.9 (C-3), 42.7 (C-3*), 45.6 (C-8a), 49.5 (C-8a*), 60.5 (OCH₂CH₃), 60.7 (OCH₂CH₃*), 168.9(NCO), 169.1 (NCO*), 173.1 (COO), 173.3 (COO*); HRMS (EI+) m/z = [MH]⁺ C₁₄H₂₄NO₃ requires 254.1751; found 254.1746.

4.7.2 ((3S,4aR,8aR)-1-Ethyldecahydroquinolin-3-yl)methanol **14**. To a solution of lithium aluminium hydride (0.187 g, 4.9 mmol) in THF (15.0 mL) at 0 °C was added acetamide **13** (0.240 g, 0.98 mmol) in THF (15.0 mL) in a dropwise manner. The resulting mixture heated at reflux, under nitrogen, for 23 h. The resulting mixture was allowed to cool to room temperature and was quenched by the dropwise addition of water (1.5 mL). The mixture was filtered through Celite and washed with ethyl acetate (20.0 mL) and the volatile solvents were removed *in vacuo* to give the *title compound* **14** (0.190 g, quant.) as a pale orange solid which was used without further purification. [α]_D²⁰ +11 (c 1.0, CHCl₃); m.p. 90-92 °C; R_F = 0.25 (4:1 ethyl acetate, n-hexanes,); v_{max} cm⁻¹ 3316, 2950, 1469, 1373, 1080, 1044, 769; δ_H (400 MHz; CDCl₃) 1.07 (3H, t, J = 7.3 Hz, NCH₂CH₃), 1.10-1.18 (1H, m, H_A-7), 1.29-1.41 (4H, m, H-5, H-8), 1.42-1.52 (2H, m, H-6), 1.53-1.60 (2H, m, H-4), 1.72-1.78 (1H, m, H_B-7), 1.83-1.94 (1H, m, H-3), 1.96-2.03 (1H, m, H-4a), 2.07 (1H, t, J = 11.5 Hz, H_A-2), 2.48-2.59 (2H, m, NCH₂CH₃), 2.71 (1H, dd, J = 11.5, 3.9 Hz, H_B-2), 2.78-2.85 (1H, m, H-8a), 3.42-3.55 (2H, m, CH₂OH); δ_C (100 MHz; CDCl₃) 12.9 (NCH₂CH₃), 16.7 (C-6), 21.0 (C-5), 25.6 (C-7), 27.2 (C-8), 32.0 (C-4), 35.2 (C-4a), 39.3 (C-3), 47.9 (NCH₂CH₃), 49.1 (C-2), 58.2 (C-8a), 66.7 (CH₂OH); HRMS (EI+) m/z = [MH]⁺ C₁₂H₂₄NO requires 198.1851; found 198.1852.

((3"S,4a"R,8a"R)-1"-Ethyldecahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxo-2',5'-dihydro-1Hpyrrol-1'-yl)benzoate 15. To a solution of alcohol 14 (0.052 g, 0.26 mmol) in dry dichloromethane (5.0 mL) was added 2-(3-methyl-2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)benzoic acid 9 (0.120 g, 0.52 mmol), DMAP (3.0 mg, 0.03 mmol) and DCC (0.107 g, 0.52 mmol) and the mixture was stirred for 18 h. The mixture was filtered through Celite and washed with ethyl acetate (30 mL). The filtered mixture was washed with aqueous NaHCO₃ (2 × 30 mL), dried (Na₂SO₄) and the volatile solvents were removed in vacuo to give the title compound 15 (0.087 g, 80%) as a green oil which was used without further purification. [α]_D²⁰ +7 (c 1.0, CHCl₃); $R_F = 0.8$ (4:1 ethyl acetate, *n*-hexanes,); v_{max} /cm⁻¹ 2928, 2854, 1712, 1453, 1393, 1258, 1108; δ_{H} (400 MHz; CDCl₃) 1.08 (3H, t, J = 7.2 Hz, NCH_2CH_3), 1.11-1.21 (1H, m, H_A -7"), 1.23-1.37 (4H, m, H-5", H-8"), 1.39-1.47 (2H, m, H-6"), 1.52-1.61 (3H, m, H-4", H_B-7"), 1.94-2.01 (1H, m, H-4a"), 2.05-2.11 (2H, m, H_A-2", H-3"), 2.16 (3H, s, 3'- CH_3), 2.45-2.60 (2H, m, NCH_2CH_3), 2.67 (1H, d, J = 8.6 Hz, H_B-2''), 2.79-2.89 (1H, m, H-8a''), 4.01-4.14 (2H, m, CH_2O), 6.50 (1H, s, H-4'), 7.29 (1H, d, J = 7.4 Hz, H-6), 7.49 (1H, t, J = 7.4 Hz, H-5), 7.63 (1H, t, J = 7.4Hz, H-4), 8.08 (1H, d, J = 7.4 Hz, H-3); $\delta_{\rm C}$ (100 MHz; CDCl₃) 11.0 (3'-CH₃), 12.8 (NCH₂CH₃), 16.6 (C-6"), 20.8 (C-5"), 25.3 (C-7"), 27.3 (C-8"), 31.5 (C-4"), 35.1 (C-4a"), 36.0 (C-3"), 47.7 (NCH₂CH₃), 48.8 (C-2"), 57.9 (C-8a"), 68.3 (CH₂O), 127.5 (C-4"), 127.8 (C-1), 128.8 (C-5), 130.2 (C-6), 131.4 (C-3), 131.6 (C-2), 133.0 (C-4), 146.1 (C-3'), 164.7 (COO), 169.5 (C-2'), 170.6 (C-5'); HRMS (EI+) $m/z = [MH]^+ C_{24}H_{31}N_2O_4$ requires 411.2278; found 411.2287.

4.7.4 ((3"S,4a"R,8a"R)-1"-Ethyldecahydroquinolin-3"-yl)methyl 2-(3'-methyl-2',5'-dioxopyrrolidin-1'-yl)benzoate **16**. To a solution of maleimide **15** (0.08 g, 0.19 mmol) in ethyl acetate (2.0 mL) was added 10% palladium on carbon (9.0 mg) and the resulting solution was stirred under hydrogen (1 atm) for 18 h. The mixture was filtered through Celite which was washed with ethyl acetate (20 mL) and the volatile solvents were removed *in vacuo* to give the *title compound* **16** (0.079 g, 99%) as a pale brown oil. [α]_D²⁰ +5 (c 1.0, CHCl₃); R_F = 0.75 (4:1 ethyl acetate, n-hexanes,); v_{max}/cm^{-1} 2927, 2840, 1711, 1491, 1380, 1110, 1108; δ_H (400 MHz;

CDCl₃) 1.00 (3H, t, J = 7.0 Hz, NCH₂CH₃), 1.19-1.26 (1H, m, H_A-7"), 1.28-1.43 (7H, m, 3'-CH₃, H-5", H-8"), 1.46-1.53 (2H, m, H-4"), 1.63-1.73 (1H, m, H_B-7"), 1.90-1.98 (1H, m, H-4a"), 2.03-2.09 (2H, m, H_A-2", H-3"), 2.38-2.53 (4H, m, H-4', NCH₂CH₃), 2.63 (1H, d, J = 7.0 Hz, H_B-2"), 2.73-2.80 (1H, m, H-8a"), 2.91-3.06 (1H, m, H-3'), 3.95-4.07 (2H, m, CH₂O), 7.13-7.23 (1H, m, H-6), 7.43 (1H, t, J = 7.0 Hz, H-5), 7.56 (1H, t, J = 7.0 Hz, H-4), 8.02 (1H, d, J = 7.0 Hz, H-3); $\delta_{\rm C}$ (100 MHz; CDCl₃) 12.9 (NCH₂CH₃), 16.2 (3'-CH₃), 16.6 (3'-CH₃*), 16.7 (C-6"), 20.8 (C-5"), 25.3 (C-7"), 27.3 (C-8"), 31.5 (C-4"), 35.1 (C-3', C-4a"), 36.1 (C-3"), 36.9 (C-4'), 47.7 (NCH₂CH₃), 48.8 (C-2"), 57.9 (C-8a"), 68.2 (CH₂O), 127.3 (C-1), 129.2 (C-5), 129.7 (C-6), 131.3 (C-2), 132.6 (C-3), 133.2 (C-4), 164.1 (COO), 171.0 (C-2'), 175.6 (C-5'); HRMS (EI+) $m/z = [{\rm MH}]^+$ C₂₄H₃₃N₂O₄ requires 413.2435; found 413.2436.

Acknowledgements

We are grateful for the financial support from The University of Auckland for a Doctoral Scholarship (ED).

References

- 1. (a) Manske, R. H. Can. J. Res. 1938, 16B, 57. (b) Goodson, J. A. J. Chem. Soc. 1943, 139-141.
- 2. (a) Jennings, K. R.; Brown, D. G.; Wright, D. P. *Experientia* **1986**, *42*, 611-613. (b) Kukel, C. F.; Jennings, K. R. *Can. J. Physiol. Pharmacol.* **1994**, *72*, 104-107. (c) Macallan, D. R. E.; Lunt, G. G.; Wonnacott, S.; Swanson, K. L.; Rapoport, H.; Albuquerque, E. X. *FEBS Lett.* **1988**, *226*, 357-363. (d) Reina, M.; González-Coloma, A. *Phytochem. Rev.* **2007**, *6*, 81-95.
- 3. Wonnacott, S.; Alburquerque, E. X.; Bertrand, D. Methods Neurosci. 1993, 12, 263-275.
- 4. Alexander, J.; Bindra, D. S.; Glass, J. D.; Holahan, M. A.; Renyer, M. L.; Rork, G. S.; Sitko, G. R.; Stranieri, M. T.; Stupienski, R. F.; Veerapanane, H.; Cook, J. J. J. Med. Chem. **1996**, *39*, 480-486.
- 5. Lloyd, G. K.; Williams, M. J. Pharm. Exp. Ther. 2000, 292, 461-467.
- 6. (a) Tsuneki, H.; You, Y.; Toyooka, N.; Kagawa, S.; Kobayashi, S.; Sasaoka, T.; Nemoto, H.; Kimura, I.; Dani, J. A. *Mol. Pharmacol.* **2004**, *66*, 1061-1069; (b) Toyooka, N.; Tsuneki, H.; Kobayashi, S.; Zhou, D.; Kawasaki, M.; Kimura, I.; Sasaoka, T.; Nemoto, H. *Curr. Chem. Biol.* **2007**, *1*, 97-114.
- 7. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. J. Med. Chem. 2005, 48, 4705-4745.
- 8. Manners, G. D.; Panter, K. E.; Pelleteir, S. W. J. Nat. Prod. 1995, 58, 863-869.
- 9. (a) McKay, D. B.; Chang, C.; Gonzalez-Cestari, T. F.; Mckay, S. B.; El-Hajj, R. A.; Bryant, D. L.; Zhu, M. X.; Swaan, P. W.; Arason, K. M.; Pulipaka, A. B.; Orac, C. M.; Bergmeier, S. C. *Mol. Pharmacol.* 2007, 71, 1288-1297. (b) Bryant, D. L.; Free, R. B.; Thomasy, S. M.; Lapinsky, D. J.; Ismail, K. A.; McKay, S. B.; Bergmeier, S. C.; McKay, D. B. *Neurosci. Res.* 2002, 42, 57-63. (b) Bergmeier, S. C.; Lapinsky, D. J.; Free, R. B.; McKay, D. B. *Bioorg. Med. Chem. Lett.* 1999, 9, 2263-2266; (c) Bryant, D. L.; Free, R. B.; Thomasy, S. M.; Lapinsky, D. J.; Ismail, K. A.; Arason, K. M.; Bergmeier, S. C.; McKay, D. B. *Ann. N. Y. Acad. Sci.* 2002, 971, 139-141; (e) Bergmeier, S. C.; Ismail, K. A.; Arason, K. M.; McKay, S.; Bryant, D. L.; McKay, D. B. *Bioorg. Med. Chem. Lett.* 2004, 14, 3739-3742; (f) Ismail, K. A.; Bergmeier, S. C. *Eur. J. Med. Chem.* 2002, 37, 469-474; (h) Huang, J.; Orac, C. M.; McKay, S.; McKay, D. B.; Bergmeier, S. C. *Bioorg. Med. Chem.* 2008, 16, 3816-3820.
- 10. (a) Barker, D.; McLeod, M. D.; Brimble, M. A.; Savage, G. P. *Tetrahedron Lett.* **2001**, *42*, 1785-1788; (b) Sparrow, K. J.; Carley, S.; Sohnel, T.; Barker, D.; Brimble, M. A. *Tetrahderon* **2015**, *71*, 2210-2221. (c) Goodall, K. J.; Brimble, M. A.; Barker, D. *Tetrahedron* **2012**, *68*, 5759-5778. (d) Sparrow, K. J.; Barker, D.; Brimble, M. A. *Tetrahedron* **2012**, *68*, 1017-1028. (e) Sparrow, K. J.; Barker, D.; Brimble, M. A. *Tetrahedron* **2011**, *67*, 7989-7999. (f) Chan, Y.; Balle, J.; Sparrow, K. J.; Boyd, P. D. W.; Brimble, M. A.; Barker, D. *Tetrahedron* **2010**, *66*, 7179-7191. (g) Chan, Y.; Guthmann, H.; Brimble, M. A.; Barker, D. *Synlett* **2008**, *17*, 2601-2604. (h) Goodall, K. J.; Brimble, M. A.; Barker, D. *Magn. Reson. Chem.* **2008**, *46*, 75-79. (i) Goodall, K.

- J.; Brimble, M. A.; Barker, D. *Magn. Reson. Chem.* **2007**, *45*, 695-699. (j) Goodall, K. J.; Brimble, M. A.; Barker, D. *Magn. Reson. Chem.* **2006**, *44*, 980-983. (k) Lehmann, A.; Brocke, C.; Barker, D.; Brimble, M. A. *Eur. J. Org. Chem.* **2006**, *14*, 3205-3215. (l) Barker, D.; Lin, D. H.-S.; Carland, J. E.; Chu, C. P.-Y.; Chebib, M.; Brimble, M. A.; Savage, G. P.; McLeod, M. D. *Bioorg. Med. Chem.* **2005**, *13*, 4565-4575. (m) Barker, D. Brimble, M. A.; McLeod, M. D. *Tetrahedron* **2004**, *60*, 5953-5963. (n) Barker, D.; Brimble, M. A.; McLeod, M. D.; Savage, G. P. *Org. Biomol. Chem.* **2004**, *2*, 1659-1669. (o) Barker, D.; Brimble, M. A.; McLeod, M. D.; Savage, G. P. *Tetrahedron Lett.* **2002**, *43*, 6019-6022. (p) Barker, D.; Brimble, M. A.; McLeod, M. D.; Savage, G. P.; Wong, D. J. *J. Chem. Soc., Perkin Trans. 1*, **2002**, *7*, 924-931. (q) Goodall, K. J.; Barker, D.; Brimble, M. A. *Synlett* **2005**, 1809-1827.
- 11. (a) Doisy, X.; Blagbrough, I. S.; Wonnacott, S.; Potter, B. V. L. *Pharm. Pharmacol. Commun.* **1998**, *4*, 313-317; (g) Simoni, D.; Rossi, M.; Rondanin, R.; Baruchello, R.; Grisolia, G.; Eleopra, M.; Giovannini, R.; Bozzoli, A.; Davalli, S.; Di Fabio, R.; Donati, D. *Tetrahedron Lett.* **2005**, *46*, 759-762.
- 12. (a) Guthmann, H.; Conole, D.; Wright, E.; Koerber, K.; Barker, D.; Brimble, M. A. *Eur. J. Org. Chem.* **2009**, 1944-1960. (b) Huang, J.; Bergmeier, S. C. *Tetrahedron* **2008**, *64*, 6434-6439.
- 13. (a) Horii, Z.; Watanabe, T.; Ikeda, M.; Kurihara, T.; Tamura, Y. *Yakugaku Zasshi* **1964**, *84*, 142–145. (b) Cassady, J. M.; Li, G. S.; Spitzner, E. B.; Floss, H. G.; Clemens, J. A. *J. Med. Chem.* **1974**, *17*, 300-307.
- 14. Weijers, C. A. G. M.; Konst, P. M.; Franssen, M. C. R.; Sudholter, E. J. R. *Org. Biomol. Chem.* **2007**, *5*, 3106-3114.
- 15. (a) Villieras, J.; Rambaud, M. *Org. Synth.* **1988**, *66*, 220-224. (b) Byun, H.-S.; Reddy, K. C.; Bittman, R. *Tetrahedron Lett.* **1994**, *35*, 1371-1374. (c) Hediger, M. E. *Bioorg. Med. Chem.* **2004**, *12*, 4995-5010.
- 16. Barker, D.; Brimble, M. A.; McLeod, M. D. Synthesis 2003, 656-658.